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9ABSTRACT
Sputum induction by inhalation of hypertonic saline using an ultrasonic nebulizer is a
non-invasive procedure allowing assessment of airway inflammation. In the studies de-
scribed in this thesis, we used a method of sputum induction in patients with chronic ob-
structive pulmonary disease (COPD), asthma, respiratory symptoms suggestive of asth-
ma, prolonged cough, and healthy persons. Subjects were recruited from the outpatient
clinics of two University Hospitals and from primary care. Both adults and children took
part. Sputum cells associated with inflammation on cytospins or smears and markers of
eosinophil and neutrophil activation were studied at baseline and after anti-inflammatory
treatment.
Sputum induction was found to be a safe and reproducible method allowing study of
airway inflammation even when disease was severe. Since inhalation of hypertonic saline
can result in bronchoconstriction, there should be pre-treatment with a bronchodilator,
and lung function should be monitored during sputum induction.
Marked sputum neutrophilia was noted in patients with COPD. However, there was a
subgroup of COPD patients with eosinophilic airway inflammation. Immunostaining re-
vealed very few lymphocytes.
A patient group with symptoms suggestive of asthma and signs of airway eosi-
nophilia but no significant airflow limitation was characterised. The degree of eosi-
nophilic airway inflammation was less pronounced than in asthma. The patients respond-
ed to treatment with inhaled steroids. There is no agreed definition or diagnostic criteria
for this condition. Its occurrence and the effects of various kinds of treatments need sys-
tematic studies.
The method of sputum induction studied can be safely and successfully used in as-
sessing airway inflammation in children with newly detected asthma. Six months of
treatment with inhaled budesonide improved lung function, controlled asthma well, and
decreased numbers of sputum eosinophils. Regular treatment with low doses of inhaled
steroid for 18 months resulted in further clinical improvement but the results were not
significantly different from those obtained using treatment during exacerbations only.
Eosinophilic airway inflammation is fairly commonly associated with prolonged
cough in primary care, even in patients not suffering from asthma or COPD, or in whom
no other cause of cough is known to be present. Induced sputum samples obtained in
health centres could be studied in a central laboratory. Detection of eosinophilic airway
inflammation could aid decisions regarding treatment.
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INTRODUCTION
A recent advance to extend our understanding of asthma, COPD and other airway diseases
has been introduction of a direct, relatively non-invasive, method of induction of sputum
production involving subjects inhaling hypertonic saline (Pin et al. 1992a). The cellular and
non-cellular compositions of sputum depend on many biological processes within the respi-
ratory system. Determination of sputum composition is a valuable tool in studying such
processes (Gibson et al. 1989a). Since the late 1980s sputum induction has become one of
the most widely used methods for the study of airway inflammation in disease. A PubMed
search of abstracts containing the key words asthma or COPD and induced sputum resulted
in identification of more than 400 articles published during the last 10 years. They include
several editorials and reviews. An international group of researchers has formed a task
force, supported by the European Respiratory Society (Djukanovic 2000), to evaluate the
merits of techniques of sputum induction and processing of samples and suggest ways of
improving them.
The importance of measuring airway inflammation in chronic respiratory conditions
such as asthma, COPD and prolonged cough has recently been emphasised (Gibson
2000). The Finnish National Asthma Programme in 1994 and the COPD Programme in
1998 stressed the importance of early diagnosis and treatment of these diseases (Haahtela
and Laitinen 1996, Laitinen and Koskela 1999). Asthma often begins in childhood and
may become persistent by adulthood. It is important to evaluate airway inflammation in
children to determine what role it may play in the genesis of asthma. A simple method al-
lowing characterisation of airway inflammation is therefore likely to be valuable.
Several research groups have used sputum induction in characterising patients with
chronic cough (Gibson et al. 1989b, Brightling et al. 1999a, Fujimura et al. 2000). Eosi-
nophilic airway inflammation characteristic of asthma is common in such patients. How-
ever, little is known about the occurrence of this condition, its natural history, or the ef-
fects of various anti-inflammatory treatments.
The studies described in this thesis were designed to allow investigation of clinical
applications of sputum induction method in various patient populations. We wanted to as-
sess how safe, successful and reproducible the method might be, and to compare inflam-
matory cells and mediators in sputum from patients with COPD, asthma and chronic res-
piratory symptoms suggesting asthma. We also investigated use of the method in children
with asthma and analysed the effects of various anti-inflammatory treatments on markers
in sputum. One aim was to relate inflammatory changes to such clinical characteristic of
patients as their symptoms and airway function.
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REVIEW OF THE LITERATURE
DEFINITIONS
Chronic obstructive pulmonary disease (COPD)
COPD is a major cause of morbidity and mortality. The main factor associated with it is
cigarette smoking. Clinically, COPD is defined as a disorder characterised by the exist-
ence of airflow obstruction associated with chronic bronchitis or emphysema. The air-
flow obstruction is generally progressive and irreversible but may be accompanied by air-
way hyperresponsiveness, and may be partly reversible (ATS 1987a and 1995). Three
disorders have, historically, been included in COPD: emphysema, peripheral airways dis-
ease and chronic bronchitis. Any patient can have from one to three of these conditions.
Emphysema is defined anatomically as destructive enlargement of the airspace distal to
the terminal bronchiole, primarily the alveolar area, without obvious fibrosis (Snider et
al. 1985). Various morphological abnormalities have been identified in peripheral airways
disease. They include inflammation of the terminal and respiratory bronchioles, fibrosis
of airway walls with consequent narrowing, and goblet cell metaplasia of the bronchial
epithelium (ATS 1995). Chronic bronchitis has been defined clinically as the condition of
subjects with cough and excessive mucus secretion occurring on most days for at least
three months of the year for at least two successive years (ATS 1987a).
Chronic bronchitis can occur with or without airway obstruction. Approximately
50% of heavy smokers develop mucous hypersecretion. A minority, perhaps only 10 to
15%, develops chronic airflow obstruction (US Surgeon General 1984). Bronchoscopic
studies of subjects with COPD have shown increased total numbers of cells and neu-
trophils in bronchoalveolar lavage (BAL) fluid (Martin et al. 1985, Thompson et al.
1989). In studies of bronchial biopsy samples, subjects with chronic bronchitis were
found to have increased numbers of macrophages and activated T lymphocytes (Saetta et
al. 1993). It has recently been have suggested that eosinophilic airway inflammation con-
tributes to airflow obstruction in some patients with COPD, and that the short-term ef-
fects of oral prednisolone are a result of modification of this feature of the inflammatory
response (Chanez et al. 1997, Pizzichini et al. 1998a, Brightling et al. 2000a).
Asthma
Asthma is a major chronic airway disease, the prevalence of which is increasing in Fin-
land and throughout the world (ISAAC 1998, Haahtela et al. 1990, Pallasaho et al. 2000,
Kilpeläinen 2001). Asthma affects people of all ages and places considerable burdens on
health-care budgets (Weiss et al. 1992, Haahtela et al. 2001). Asthma is currently defined
as a chronic inflammatory airway disease in which many cells, in particular mast cells,
eosinophils, and T lymphocytes, play roles. In susceptible individuals, the inflammation
causes recurrent episodes of wheezing, breathlessness, chest tightness and cough. The
symptoms are usually associated with variable airflow limitation that is at least partly re-
versible, spontaneously or with treatment. Chronic airway inflammation is associated
12
with increases in airway responsiveness to various stimuli (NHLBI/WHO 1995). Airway
inflammation in asthma is characterised by vascular leakage, mucus hypersecretion, epi-
thelial shedding, and extensive airway narrowing. Apart from cells conventionally associ-
ated with inflammation, structural tissue cells, such as epithelial cells, fibroblasts and
smooth muscle cells, play significant roles in relation to airway inflammation, through
release of a variety of mediators (Chung and Barnes 1999). Chronic airway inflammation
stimulates mechanisms of airway healing and repair that can lead to progressive, poten-
tially irreversible, tissue destruction and airway remodelling (Vignola et al. 2000). Some
patients with asthma and COPD share pathological features (Barnes 2000). Some investi-
gators believe it is impossible to regard the two conditions as wholly separate (Sluiter et
al. 1991) (Fig. 1).
Asthma-like symptoms, chronic cough with eosinophilic bronchitis
Diagnosis of asthma is based on establishing variable airway obstruction. Improvement
of airway narrowing, as indicated by an increase of more than 12 to 15% in forced expir-
atory volume in one second (FEV1) or in peak expiratory flow values (PEF), spontane-
ously or after using a bronchodilator, indicates asthma (NHLBI/WHO 1995). Reversibili-
ty in relation to bronchodilators and variability of lung volumes or PEF values exhibit,
however, continuous distributions (Higgins et al. 1989), and the cut-off limit of 15% is
fairly arbitrary. Within the Finnish National Asthma Programme it has been estimated
that roughly 10% of the population, apart from asthma patients proper, occasionally ex-
hibit symptoms suggestive of mild asthma even though results of lung-function tests re-
main normal or close to normal (Haahtela and Laitinen 1996). The symptoms in such
subjects include cough, chest tightness with wheezing, shortness of breath, sputum pro-
duction, and wheezing or cough during exercise. Chronic cough is a problem commonly
encountered in primary health-care. It can indicate or precede asthma. In practice, many
patients exhibit symptoms that give rise to suspicion of asthma but results of lung-func-
tion tests do not vary significantly from normal. In such patients no specific diagnosis is
usually reached.
Eosinophilic bronchial inflammation is found in patients with newly detected or mild
intermittent asthma (Laitinen et al. 1993, Vignola et al. 1998a) but also in some patients
with chronic cough and normal lung function (Gibson et al. 1989b and 1995, Brightling
10%
COPD ASTHMA
• Neutrophils
• No airway
hyperreactivity
• No bronchodilator
response
• No corticosteroid
response
• Eosinophils
• Airway
hyperreactivity
• Bronchodilator
response
• Corticosteroid
response
Fig. 1
Overlap between COPD and asthma (Barnes 2000).
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et al. 1999a, Carney et al. 1997, Brightling and Pavord 2000). The term eosinophilic
bronchitis has also been used in relation to subjects with asthma-like symptoms related to
work but no asthma proper, and with sputum eosinophils (Lemière et al. 1997). Other re-
searchers have used the term eosinophilic tracheobronchitis (Fujimura et al. 2000). Pa-
tients with chronic cough responsive to corticosteroids have been found to resemble pa-
tients with asthma in relation to gene expression of some cytokines found in cells in BAL
fluid (Gibson et al. 1998a), and in relation to various inflammatory mediator concentra-
tions (Brightling et al. 2000b).
ASSESSMENT OF AIRWAY INFLAMMATION
Airway inflammation is considered to be a major cause of exacerbations in asthma and
COPD and of permanent structural alterations of the airways in these conditions (Vignola
et al. 2000). Consensus guidelines state that treatment of asthma should be directed pri-
marily towards minimisation of inflammation (NHLBI 1997). However, it has not so far
been possible in clinical practice to measure airway inflammation directly. The presence
and nature of airway inflammation have been deduced from indirect measurements, e.g.
of lung function, and from symptoms, results of physical examination and the effects of
treatment. The association between degree of lung-function abnormality and underlying
inflammation is not straightforward (Crimi et al. 1998). Correspondingly, in patients with
COPD there is a need to discover markers that would allow prediction of long-term re-
sponse to treatment with inhaled corticosteroids (Pauwels et al. 1999, Brightling et al.
2000a). Patients with chronic cough cannot be diagnosed as suffering from eosinophilic
bronchitis unless airway inflammation has been studied (Carney et al. 1997).
Asthma often begins in childhood. It may become persistent by adulthood. There is
an increasing tendency to treat it preventively with inhaled corticosteroids, in both chil-
dren and adults (NHLBI 1997). The rationale is that the inflammatory process is similar
in children and adults. However, airway inflammation in childhood asthma has not been
so well characterised as in adults.
Direct measurement of airway inflammation
Bronchial biopsies and bronchoalveolar lavage (BAL)
Use of rigid or fibre-optic bronchoscopy to obtain bronchial biopsy samples or perform
BAL, segmental allergen challenge, and bronchial brushing has contributed significantly
to current knowledge relating to asthma and COPD (Jarjour et al. 1998). It has been
shown to be feasible to measure airway inflammation via bronchial biopsy samples and
BAL fluid. Results of measurements have been shown to be responsive to change (Laitin-
en et al. 1992, Djukanovic et al. 1992a). However, it is difficult to quantify changes ob-
served in relation to bronchial biopsy samples, and reproducibility has been reported to
be poor (Ward et al. 1995, Richmond et al. 1996). The invasiveness of the procedure, as-
sociated costs, and restriction of its use to subjects with mild or moderate and stable dis-
ease make bronchoscopy unsuitable for monitoring airway inflammation in clinical prac-
tice (Djukanovic et al. 1991, Workshop Summary and Guidelines 1991, Jarjour et al.
1998) (Table 1).
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Table 1. Advantages and disadvantages of bronchial biopsy, BAL fluid examination, induced spu-
tum examination and exhaled NO determination (modified from Workshop Summary and Guide-
lines 1991, Jarjour et al. 1998, Djukanovic 2000, Jatakanon et al. 1999a)
Advantages Disadvantages
Bronchoscopy • Allows biopsy and BAL: samples
can be obtained from mucosal
tissue and of cells and mediators
from airway lumen
• Provides information on structural
changes (relating to epithelium,
basement membrane, lamina
propria)
• Can be followed by
immunohistochemistry, in situ
hybridisation, electron microscopy
• Can be followed by segmental
allergen challenge
• Allows the use of bronchial wash
(cells for in vitro study)
• Requires trained personnel and
expensive equipment
• Invasive
• Cannot be undertaken repeatedly or
in severe disease
• BAL fluid
• relates to only one segment of the
distal lung
• there is mixing of contents of
alveolar and bronchial compartments
• is primarily saline
• can be contaminated with blood
• Biopsy samples
• can only be obtained from the 
larger airways
• cell count reproducibility is low
Induced sputum • Relatively non-invasive
• Allows samples to be obtained 
from several proximal airways
• Can be undertaken repeatedly
• Safe even in severe disease
• No expensive equipment required
• Allows study of large patient
populations
• Risk of bronchoconstriction
• Success rate around 80%
• Processing methods fairly
laborious
• Results not available immediately
Exhaled NO
determination
• Non-invasive
• Use of rapid detectors allows results
to be obtained immediately
• Can be done repeatedly
• Safe even in severe disease
• Quick
• Allows study of large patient
populations
• Equipment needed is expensive
• Determination is flow-dependent
• Contamination with nasal material 
is possible
• Only one mediator is detected
• Method is very sensitive to steroid
administration
Exhaled air
Exhaled air contains many substances. In the past few years there has been intense research
into the role played by nitric oxide (NO) in the physiology and pathology of airway diseas-
es and its clinical significance in respiratory diseases (Kharitonov and Barnes 2000). The
NO molecules originate from L-arginine and are converted to L-citrullin by the NO-syn-
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thase enzyme (NOS). One of the isoforms of this enzyme, inducible NOS, is induced by cy-
tokines. Levels of NO, which can be determined using chemiluminescence analysers, are
high in air exhaled by asthmatic patients (Alving et al. 1993, Kharitonov et al. 1994) but de-
crease after steroid treatment (Kharitonov et al. 1996, Berlyne et al. 2000). Preliminary re-
ports relating to measurements of other inflammatory mediators and markers in exhaled
breath condensate has recently been published (Montuschi et al. 1999).
Sputum
History
Sputum is defined as expectorated lower respiratory secretions (Hargreave et al. 1997,
Dorland’s Illustrated Medical Dictionary 1988). Hippocrates considered sputum to be
one of the four essential humours of the body. Sputum contains bronchial secretions from
the respiratory epithelium and submucosal gland cells. Ciliary beating and the cough
mechanism primarily control clearance of these secretions. Sputum also contains inflam-
matory cells that have migrated from the blood through the vascular endothelium and
across respiratory tissue into the bronchial lumen (Hansel and Walker 1992).
Over 100 years ago, Gollasch found eosinophilic leukocytes in sputum from asthmat-
ic patients (Gollasch 1889, Ellis 1908). Sputum from asthmatic patients occasionally also
contains clusters formed by eosinophils, so-called Charcot-Leyden crystals (Dor et al.
1984). It has been known for a long time that bronchial epithelium is damaged in asthma.
Curschmann found clusters of shedded epithelial cells in acute asthma in 1885 (Cur-
schmann 1885). He also noted the presence of corkscrew-shaped twists of condensed
mucus (Curschmann’s spirals). The clusters of epithelial cells were later called Creola’s
bodies (Naylor 1962). From the 1950s to 1980s, many investigators analysed sputum mi-
croscopically and measured fluid-phase components of sputum in attempts to diagnose
asthma and chronic bronchitis, and assess disease severity (Brown 1958, Chodosh et al.
1962, Chodosh 1970, Turnbull et al. 1977,  O´Connell et al. 1978, Viera and Prolla 1979,
Dor et al. 1984). However, the methods used were considered difficult and unreliable.
In the 1950s, sputum testing was developed in connection with diagnosis of lung
cancer and tuberculosis. Since not all patients could provide sputum samples spontane-
ously, some were asked to inhale hypertonic saline, to allow demonstration of malignant
cells (Bickermann et al. 1958) or tuberculosis bacteria in sputum specimens. In relation
to asthma, international interest in sputum testing arose after it was observed that epithe-
lial damage and inflammatory changes are present even in early-stage asthma (Laitinen et
al. 1985). In 1992, Pin et al. induced sputum production with the help of hypertonic sa-
line to allow determination of eosinophilic inflammation in asthmatic patients.
Cleland (1964) identified dithiothreitol (DTT) and its isomer, dithioethreitol (DTE),
as agents with low redox potentials, which could reduce and split mucoprotein disulphide
bonds. Shah and Dye (1965) showed treatment with DTT and DTE allowed dispersion of
sputum before processing of smears and cultures for mycobacteria. The agents were not
used to process sputum for cell examination until 1978 (Wooton and Dulfano 1978).
From 1989, Gibson et al. demonstrated that cell counts using smears of sputum selected
from saliva were reproducible and allowed demonstration of asthmatic inflammation.
However, it is difficult to identify different types of cell in smears without using special
stains (Pin et al. 1992a). In subsequent developments, DTT or DTE have been used to
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disperse mucus, cytospins have been made from cell suspensions, and fluid phases have
been collected for measurement of molecular components (Hansel et al. 1991, Virchow et
al. 1992, Fahy et al. 1993a, Popov et al. 1994).
Induced sputum
Sputum production is induced to allow collection of adequate samples of secretions from
the lower airways for assessment of airway inflammation in patients unable to produce
sputum spontaneously. It has been shown that inhalation of isotonic or hypertonic solu-
tions via an ultrasonic nebulizer induce production of small amounts of secretions from
the airways. These secretions can be expectorated and analysed. The mechanisms under-
lying the process are largely unknown. It is believed that increased osmolarity of airway
lining fluid increases vascular permeability in the bronchial mucosa and production of
mucus by submucosal glands. Hypertonic saline has been shown to increase bronchovas-
cular permeability in rat trachea (Umeno et al. 1990) but there is no information about
how the mucous-secreting cells in the airways are stimulated. It has been shown that
clearance of secretions from the airways in human beings is increased after administra-
tion of a hypertonic saline aerosol (Pavia et al. 1978). Our clinical experience is that sa-
line inhalation induces coughing, which helps clear the pre-existing sputum from air-
ways. Details of the induced sputum method are discussed below.
Indirect measurement of airway inflammation
Clinical features
Direct indices of airway inflammation can correlate with clinical parameters such as
symptoms, degree and variability of airflow limitation, and airway responsiveness (Vir-
chow et al. 1992, Pizzichini et al. 1996a, Gibson et al. 1992, Pin et al. 1993, Keatings et
al. 1997a). However, correlation is not universal and changes in these parameters may not
be similar or simultaneous (Pizzichini et al. 1997a). Correlations between clinical param-
eters can vary considerably (Kendrick et al. 1993) or be conflicting (Siersted et al. 1996).
It is difficult to judge the nature or degree of airway inflammation from clinical parame-
ters (Prameswaran et al. 2000a).
Peripheral blood
Peripheral blood eosinophilia is often found in asthma. Correlations have been observed
between it and severity of symptoms, degree of airflow limitation and airway responsive-
ness to methacholine or histamine (Bousquet et al. 1990, Ulrik 1995). More recently, it
has been suggested that the state of activation of blood eosinophils, as measured by levels
of eosinophil activation markers, e.g. eosinophilic cationic protein (ECP), might be a use-
ful indirect marker of airway inflammation (Griffin et al. 1991, Juntunen-Backman et al.
1993). However, results of analyses relating to sputum may reflect inflammatory process-
es more accurately than results of blood and serum measurements (Pizzichini et al.
1996b, Metso et al. 1996, Sorva et al. 1997, Piacentini et al. 1999).
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INDUCED SPUTUM
Sputum induction
Induction of sputum production involves the subject inhaling saline solution. The subject
is instructed to expectorate the small amount of secretions produced in the airways into a
sterile plastic container. Various issues that need to be considered in relation to this pro-
cedure are listed in Table 2. Although no standard method for the induction of sputum
has been agreed, consensus regarding induction of sputum production in asthma has re-
cently been proposed (Kips et al. 1998). A future European Respiratory Society Task
Force document will review the matter (Djukanovic 2000). One reason why standardisa-
tion of procedure is desirable is that inhalation of hypertonic saline can cause asthmatics
to suffer airway constriction (Smith and Anderson 1989). The mechanism of the effect is
unknown but it may involve activation of airway mast cells (Gravelyn et al. 1988) or sen-
sory nerve endings (Makker and Holgate 1993). Safety procedures include measurement
of lung function before and during sputum induction, and pre-treatment with a short-act-
ing β2-agonist.
Table 2. Issues relating to sputum induction (based on unpublished data of the European Respira-
tory Society Task Force on Induced Sputum)
Facilities, equipment and personnel
• Quiet room with water supply and ventilation
• Ultrasonic nebulizer, spirometer or peak-expiratory-flow
(PEF) meter, safety equipment,
• Sterile saline solutions, sputum cup, freezer in which to
store the sample
• Experienced nurse, medical supervision
Pre-treatment with bronchodilators
• For safety reasons pre-treat with 200 to 400 µmg of
inhaled salbutamol
Pulmonary function monitoring
• For safety reasons monitor FEV1 or PEF
• No agreed protocol: monitor before and after induction
of sputum production, at least, and always if adverse
effects appear
Nebulizer output
• Ultrasonic nebulizer preferred, several models exist
• Output varies between 0.21 and 4.6 ml/min
Concentration of saline solution
• Different concentrations have been used (0.9, 3, 4, 5%)
• Increasing concentrations or constant concentration
Duration of inhalation
• Should be standardised and reported
• Duration of between 10 and 30 minutes have been
reported
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Pre-treatment with bronchodilators
Although some investigators have not pre-treated patients, because they wished to study
the functional response of airways to the bronchoconstricting stimulus (Iredale et al.
1994, Bacchi et al. 1997, Gibson et al. 1998b), most have given short-acting β2-agonists
beforehand, to prevent excessive bronchoconstriction (Pin et al. 1992a, Jatakanon et al.
1998a, Wong and Fahy 1997). Severe asthma exacerbation, leading to death in an asth-
matic subject undergoing a distilled-water challenge, has been reported (Saetta et al.
1995). Safety reasons apart, excessive bronchoconstriction after a few minutes of inhala-
tion of hypertonic solution can necessitate interruption of induction and collection of an
insufficient amount of sputum.
In the original studies of sputum induction, few side effects were reported, and no
falls in FEV1 (Pin et al. 1992a, Fahy et al. 1993a). The safety of sputum induction has
been assessed in patients with asthma in a number of studies (Pizzichini et al. 1997a,
Wong and Fahy 1997, de la Fuente et al. 1998, Grootendorst et al. 1999, Hunter at al.
1999, ten Brinke et al. 2001) but information on patients with COPD is scarce (Maestrelli
et al. 1996, Keatings et al. 1996, Bhowmilk et al. 1998). Pre-treatment with inhaled
salbutamol has not always prevented bronchocontriction in asthma (de la Fuente et al.
1998). It has been shown that pre-treatment with a β2-agonist did not alter the cellular
constituents of induced sputum (Popov et al. 1995, Cianchetti et al. 1999).
Pulmonary function monitoring during induction
No standard approach to pulmonary-function monitoring during sputum induction has
been suggested but many authors measure pulmonary function every five to 10 minutes,
and every time symptoms occur (Iredale et al. 1994, Bacchi et al. 1997, Pin et al. 1992a,
Jatakanon et al. 1998b, Maestrelli et al. 1994). Various methods have been used: most in-
vestigators have used spirometers, some PEF meters (Wong and Fahy 1997). It has been
suggested that lung function should be measured within the first minute of sputum induc-
tion, to identify subjects who may be unusually sensitive to hypertonic saline (Pizzichini
et al. 1997a).
Concentration of saline solution and nebulizer output
The concentration of saline used for sputum induction has ranged from normal to 5%
(Iredale et al 1994, Wong and Fahy 1997, Bacchi et al. 1997). Some investigators change
concentration during the procedure, starting with 3%, increasing to 4% and 5% (Pin et al.
1992a, Pizzichini et al. 1996a). It has been suggested that sputum production should not
be induced in asthmatic patients with an FEV1 following bronchodilator administration of
less than 1 l or 60% of the predicted value (Wong and Fahy 1997, Kips et al. 1998). An
aerosol of normal saline followed by one of hypertonic saline has, however, been safely
used in patients with severe exacerbations of asthma (Pizzichini et al. 1997a). Saline con-
centration and nebulizer output would be expected to influence the safety, tolerability and
success rate of the procedure, and the cellular and biochemical characteristics of the spu-
tum induced. Hypertonic saline seems to be more effective than normal saline in relation
to induction of sputum production (Popov et al. 1995). No differences have been found
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between cell compositions of sputum induced by use of isotonic saline, hypertonic saline
and different concentrations of saline (Popov et al. 1995, Bacchi et al. 1997). In one
study, jet nebulizers were compared with ultrasonic nebulizers. The success rate was
highest with the latter (Popov et al. 1995). Success with ultrasonic nebulizers with rela-
tively low outputs has been found to be similar to those with high-output nebulizers
(Hunter et al. 1999).
Duration of inhalation
It has been found in at least two studies that the cellular and biochemical constituents of
induced sputum change during induction (Holtz et al. 1998a, Gershman et al. 1999a).
Neutrophils and eosinophils are prominent in samples collected early during induction.
Lymphocytes and macrophages are more prominent in samples collected later. Mucin
concentrations are higher in samples collected early than in those collected late, and sur-
factant concentrations are higher in samples collected later than in earlier samples (Holtz
et al. 1998a, Gershman et al. 1999). The results of these studies suggest that different
compartments of the respiratory tract are sampled at different times during sputum induc-
tion. Central airways are sampled early, peripheral airways and alveoli later (Moodley et
al. 2000).
Protocols for sputum induction differ in relation to schedules of sputum collection.
Subjects may be asked to stop inhalation at regular intervals to produce sputum, or to
stop only when an urge to cough is felt. Methods of sputum expectoration also differ. In
some protocols subjects are required to spit saliva into one container before coughing
sputum into another (Gershman et al. 1996). Some authors have suggested that the first
sputum sample should be discarded and that only subsequent samples obtained after sa-
line inhalation should be collected and analysed (Jatakanon et al. 1998a).
Sequential sputum induction
In several studies sputum production has been induced sequentially, after intervals of
only a few hours (Pin et al. 1992b, Nordenhäll et al. 2000). However, it has been suggest-
ed that frequent repetition of sputum induction can result in late airway inflammation and
affect differential cell counts in the later inductions (Pavord 1998, Richter et al. 1999).
Some authors have reported that induction of sputum eight to 24 hours after a first induc-
tion results in more neutrophils being found in the second sputum sample (Kips et al.
1995, Nightingale et al. 1998, Holtz et al. 1998b). No effects on eosinophils or other cells
associated with inflammation were seen. It has been shown that methacholine challenge
does not alter sputum eosinophil counts but may increase sputum neutrophil percentages
(Spavanello et al. 1999, Gershman and Fahy 1999).
Sputum processing
Methods of sputum processing for cell counting and fluid-phase measure-
ments
Two methods have mainly been used for processing induced sputum (Fig. 2). The first in-
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volves selecting all of the more dense portions (plugs) from expectorated samples (Pin et
al. 1992a, Pizzichini et al. 1996a), the second processing the entire expectorate, consist-
ing of sputum plus saliva (Fahy et al. 1993a). Recent modifications to this method in-
clude separate collection of saliva and sputum (Gershman et al. 1996, Keatings et al.
1996, Louis et al. 1997). Data on whether differential cell counts differ between the two
methods are conflicting. In one study a higher percentage of eosinophils in the sputum
processed using the selection method than in sputum processed using the entire expecto-
rate was reported (Spanevello et al. 1998). However, in other studies this was not found
(Peleman et al. 1995, Gershman et al. 1996, Pizzichini et al. 1996b). Both methods have
shown to yield reproducible cell counts and results relating to certain fluid phase markers
(in´t Veen et al. 1996, Pizzichini et al. 1996a).
Total and differential cell counts
Total numbers of cells have been counted manually, in a haemocytometer, and cell viabil-
ity has been determined using the trypan-blue exclusion method by most investigators
(Fahy et al. 1993a, Pizzichini et al. 1996a). Automated methods for total cell counting
and differential cell counting have been investigated and found to be unreliable (Hansel
et al. 1991, Popov et al. 1994). Differential cell counting involves counting a minimum of
400 non-squamous cells on May-Grünwald-Giemsa (MGG)-stained slides. Results are
reported as proportions of eosinophils, neutrophils, macrophages, lymphocytes and bron-
chial epithelial cells. Metachromatic staining, in which both basophils and mast cells are
identified, has been performed using the toluidine blue staining method (Fahy et al.
1993a, Pizzichini et al. 1996a, Popov et al. 1996a, Spanevello et al. 1998). Immunocyto-
chemistry can be used in relation to sputum cells (Girbis-Gabardo et al. 1994), and can
discriminate between basophils and mast cells (Gavreau et al. 2000).
    Sputum cell counts have been shown to be valid, reliable and responsive to change
(Pin et al 1992a, Popov et al. 1994, Claman et al. 1994, Pizzichini et al. 1996b, in´t Veen
et al. 1996, Spanevello et al. 1997, Ward et al. 1998). Recently, normal values for a large
population of healthy controls have been obtained (Belda et al. 2000, Spavenello et al.
2000). In some studies in situ hybridisation has been undertaken in relation to cells in in-
duced sputum samples (Olivenstein at al. 1999, Profita et al. 2000). Polymerase chain re-
action (PCR)-technique has also been employed (Gelder et al. 1995, Fireman et al.
1999a). Flow cytometry has been used to study lymphocyte subsets in sputum (Kidney et
al. 1996, Louis et al. 1997).
Fluid-phase measurements
Numerous inflammatory mediators have been measured in the fluid phase of sputum.
They include cytokines, chemokines, granulocyte proteins, markers of vascular leakage,
eicosanoids and proteases (Fahy et al. 1993b, Tomaki et al. 1995, Keatings et al. 1996,
Vignola et al. 1998b and 1999, Louis et al. 1997, Pavord et al. 1999, Tanaka et al. 2000,
Purokivi et al. 2000). Many of the assay methods used to measure these soluble media-
tors have been developed for serum or culture fluid. The reproducibilities, precisions and
validities of many of these measurements in sputum have not been investigated (Kelly et
al. 2000, Stockley and Bayley 2000).
In many studies the roles played by eosinophils and neutrophils in asthma and COPD
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process sputum within 2 hours
process the whole sputum
select plugs
Fig. 2.
Sputum processing
Homogenisation
•Add DTT (10% Sputolysin solution)
•time: 10-30 minutes
•temperature 4-37°C
•shaking water bath or tube rocker
Centrifugation
•300-500G
•time: 5-10 minutes
Filtration
•48-52  mnylon mesh
Perform total cell count
•hemocytometer
•viability with trypan blue
Make cytospins
•Giemsa stain
•Toluidine blue stain
Cell differential count
RELEASED MARKERS
TOTAL MARKERS
Homogenisation
•Add DTT (10% Sputolysin solution) and CTAB
•time: 15+60 minutes
•temperature 25°C
•tube rocker
Centrifugation
•800G
•time: 10 minutes
Make smears
•Methylene eosin stain
Semiquantitive cell count
Aspirate supernatant and store in freezer
Make fluid phase measurements
References: Pin et al. 1992a, Fahy et al. 1993, Pizzichini et al. 1996, in´t Veen et al. 1996,
Keatings et al. 1996, Louis et al. 1997, Metso et al. 2001.
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have been studied. After activation, eosinophils can release granule-derived proteins, the
most cytotoxic of which are eosinophilic cationic protein (ECP) and major basic protein
(MBP). Other markers of eosinophil activation include eosinophil protein X (EPX) and
eosinophil peroxidase (EPO) (Venge et al. 1999). Myeloperoxidase (MPO) is a protein
released from primary (azurophil) granules of neutrophils, and can serve as a marker of
neutrophil activation. Human neutrophil lipokalin (HNL) is another protein that has re-
cently been isolated and purified from secondary neutrophil granules (Xu et al. 1994). Its
function remains unknown but it may prove a better and more specific marker of neu-
trophil activation than MPO.
Simplification of sputum-processing
Sputum processing to allow preparation of cytospin slides and differential cell counting
is laborious, and can only be undertaken in larger laboratories. A prerequisite for reliable
preparation of cytospin slides and measurement of inflammatory markers is immediate
processing of sputum (Grebski et al. 1998, Louis et al. 1999). We therefore modified a
previously validated sputum-processing method (Pizzichini et al. 1996a) to improve its
clinical applicability (Metso et al. 2001) (Fig. 2). Sputum induction and collection of
sputum plugs is the same for both methods. Sputum plugs are first treated with DTT then
with the cationic detergent CTAB (cetyl-N,N,N-trimethylammonium bromide). DTT
treatment is necessary because liquefaction of sputum plugs prior to CTAB treatment is
wanted. Detergent is added to lyse cells and liberate any biochemical markers engulfed
by cells. We chose CTAB as detergent because sticky proteins like ECP can be efficiently
recovered from cell pellets by a one-hour CTAB treatment, as shown by Carlson et al.
(1994).
Our method allows sputum specimens for measurement of biochemical markers to be
frozen and stored after collection. Specimens can therefore be obtained in one place (e.g.
a health-care centre), and processed and analysed elsewhere (e.g. in a central laboratory).
This method for sputum processing gives results similar to those obtained using the refer-
ence method (Metso et al. 2001). By measuring one eosinophil activation marker, ECP,
and one neutrophil marker, MPO, using commercially available kits, eosinophilic and
neutrophilic airway inflammation can be studied with reasonable accuracy. Incubation of
reference protein with DTT and CTAB showed no negative effects on marker assays. Re-
covery of four markers (eosinophil markers ECP and EPO, neutrophil markers MPO and
HNL) ranged from 96.6% to 102.1%. The advantage of our method (which measures to-
tal markers) over the reference method (which measures released markers) is its relative
simplicity. Even a small laboratory which does not have cytocentrifuge can use it. Num-
bers of cells associated with inflammation can be studied semiquantitatively in smears
prepared using eosin/methylene-blue staining prior to freezing (Hansel 1949).
Spontaneous versus induced sputum
Some asthmatics, particularly those suffering acute exacerbations or experiencing severe
symptoms, and COPD patients can produce sputum spontaneously. It has been shown
that spontaneous sputum samples contain percentages of cells and mediators associated
with inflammation similar to those found in induced sputum samples (Pizzichini et al.
1996c, Bhowmik et al. 1998). However, the viabilities of cells in spontaneous sputum
samples is considerably lower than that of cells in induced sputum samples (Pizzichini et
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al. 1996, Bhowmik et al. 1998), perhaps because mucus secretion stays longer in the air-
ways in the first case. Distinction between different types of cells associated with inflam-
mation is therefore more difficult.
Comparison between direct measurements of airway inflammation
There have been few direct comparisons in relation to asthma and COPD of results ob-
tained following bronchoscopy and through study of induced sputum samples (Fahy et al.
1995a, Maestrelli et al. 1995, Grootendorst et al. 1997, Keatings et al. 1997a, Pizzichini
et al. 1998b, Rutgers et al. 2000). The results of these studies allow the conclusion that
there are marked differences between the two methods, i.e. they complement each other
as research tools (Djukanovic 2000) (Table 1). Differential cell counts obtained using
BAL fluid and induced sputum samples differ even when the volume of physiological sa-
line is limited to achieve so-called bronchial wash (Fahy et al. 1995a, Keatings et al.
1997). However, in asthma, eosinophil counts correlate with each other (Grootendorst et
al. 1997). Higher concentrations of several mediators have been found in sputum samples
than in BAL fluid (Fahy et al.1995a) but they correlate better than differential cell counts
(Rutgers et al. 2000).
In several studies in asthmatics good correlations have been found between numbers
of sputum eosinophils and levels of exhaled NO both in adults and children (Jatakanon et
al. 1998b, Mattes et al. 1999). Correlation was poorer in steroid-treated asthmatics (Pia-
centini et al. 1999, Berlyne at al. 2000). Poor correlation between numbers of eosinophils
in bronchial biopsy samples and levels of exhaled NO has been reported (Lim et al.
2000).
Clinical applications of assessment of induced sputum
Induced sputum cell counts can accurately discriminate between eosinophilic and non-
eosinophilic airway inflammation, and help guide therapy (Jayaram et al. 2000). Studies
on large numbers of subjects can be conducted using induced-sputum methods (Louis et
al. 2000a), something that is clearly not easy when bronchoscopy is used. By studying
subjects with varying degrees of disease severity, insights into determinants of disease
persistence and severity can be gained.
It has been argued that sputum eosinophils are more responsive to intervention than
blood measurements but not as hypersensitive as exhaled NO levels (Jatakanon et al.
1999a). Induced sputum samples have been used to study anti-inflammatory effects of
oral and inhaled corticosteroids in adult asthma (Claman et al. 1994, Fahy and Boushey
1998, Lim et al. 1999, Jatakanon et al. 1999a, Gershman et al. 2000, Metso et al. 2000).
They have also been used in studies of other anti-inflammatory drugs, such as leukotriene
antagonists (Pizzichini et al. 1999a), theophylline (Louis et al. 2000b) and novel agents
such as anti-IgE antibodies (Fahy et al. 1997). They have been employed in clinical trials
of various combinations of treatment (Kips et al. 2000). Reports of studies of effects of
treatment in COPD patients have been published (Keatings et al. 1997b, Pizzichini et al.
1998a, Brightling et al. 2000a).
Induced sputum in children
Induced sputum has been used to study asthma in children since the technique was first
described, in 1992 (Pin et al. 1992b). The method has particular advantages in the study
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of asthma in childhood because it is relatively non-invasive. In some studies (Gibson et
al. 1998b, Oh et al. 1999) hypertonic saline challenge has been used to assess airway re-
sponsiveness and to induce sputum production. In other studies, pre-treatment with bron-
chodilators has been employed, and sputum induction has been found safe.
Most studies in which sputum production has been induced in children have been
cross-sectional, with the asthma in a stable state or the patients suffering acute exacerba-
tions (Twaddel et al. 1996, Cai et al. 1998, Gibson et al. 1999, Grootendorst et al. 1999,
Piacentini et al. 1999, Wilson et al. 2000, Norzila et al. 2000). In children with stable
asthma, numbers of eosinophils and mast cells were found to be higher than normal. Dur-
ing acute exacerbations, numbers of neutrophils, mast cells and eosinophils were higher
than normal (Twaddel et al. 1996). No data relating to airway inflammation shortly after
diagnosis of childhood asthma or from controlled trials of the effects of various anti-in-
flammatory treatments are available. Children with cystic fibrosis have been found to
have intense sputum neutrophilia (DeBoeck et al. 2000).
Induced sputum in other diseases
Processes like gastroesophageal reflux and left ventricular heart failure lead to accumula-
tions of lipids or haemosiderin in sputum macrophages. It has recently been suggested
that detection of these markers in sputum macrophages could indicate the existence of
one or other of these diseases (Parameswaran et al. 2000b, Leigh et al. 1999). In intersti-
tial lung diseases, such as sarcoidosis and idiopathic pulmonary fibrosis, lymphocytes
obtained from BAL fluid and induced sputum samples have been studied by means of
flow-cytometry. Results were similar with the two methods of obtaining the lymphocytes
(Fireman et al. 1999b, D´Ippolito et al. 1999). Induced sputum has been also been used
to assess for example exposure to hazardous dust, and pulmonary involvement in Crohn´s
disease (Fireman et al. 1999a and 2000).
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AIMS OF THE STUDY
1. To assess the safety, success rate and reproducibility of sputum induction in patients
with COPD of varying severities, and to characterise airway inflammation in them.
2. To test the hypothesis that eosinophilic airway inflammation is common in patients
with prolonged respiratory symptoms suggestive of asthma, irrespective of lung
function, and to investigate the effects of anti-inflammatory treatment with inhaled
corticosteroid in such patients.
3. To assess airway inflammation in children of five to 10 years of age shortly after
diagnosis of asthma, and to investigate the effects of treatment with regular or periodic
inhaled corticosteroid.
4. To test a simplified method of analysis of induced sputum in primary health-care and
to assess airway inflammation in patients with prolonged cough.
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SUBJECTS AND METHODS
STUDY POPULATIONS AND DESIGNS
Three hundred and eighty-one subjects participated in the studies. All of the patients and
controls were Caucasian. Local Ethics Committees had approved the studies. All subjects
gave consent to participation in the studies. In study IV, informed consent was given by
signatures of parents and children over seven years of age. The main characteristics of
the study populations are shown in Table 3.
Table 3. Diagnoses, clinical data and baseline lung function in patients and control subjects.
Studies and Diagnoses Sex Age Atopic* Smokers* FEV1
(f/m) (years) (% of predicted)†
Study I
COPD (n = 28) 9/19 60 (51 - 68) 1 (4%) 28 (100%) 53 (28 - 60)
Study II
COPD (n = 21) 2/19 61 (45 - 76) 0 (0%) 21(100%) 54 (23 - 80)
Healthy controls (n = 16) 2/14 30 (22 - 53) 0 (0%) 0 (0%) nd
Study III
Respiratory symptoms (n = 36) 33/3 39 (19 - 60) 19 (53%) 8 (22%) 95 (74 - 119)
Asthma (n = 25) 16/9 38 (15 - 75) 14 (56%) 9 (36%) 79 (57 - 105)
Healthy controls (n = 43) 27/16 36 (23 - 54) 10 (23%) 4 (9%) 98 (77 - 212)
Study IV
Asthma (n = 60) 25/35 8 (5 - 10) 37 (62%) 0 (0%) 91 (69 - 116)
Healthy controls (n = 17) 10/7 9 (5 - 13) 7 (41%) 0 (0%) 95 (79 - 118)
Study V
Prolonged cough (n = 82) 25/57 46 (16 - 85) 12 (15%) 23 (28%) 82 (41 - 111)
Healthy controls (n = 53) 43/10 42 (25 - 61) 9 (17%) 3 (6%) nd
Data are expressed as means and ranges, and numbers and percentages*, COPD = chronic obstructive
pulmonary disease, f = female, m = male, nd = not done
†Reference values from Viljanen (Viljanen 1982) studies I, III and V, European Community for Coal and Steel
(Quanjer et al. 1993) study II, Polgar and Prodmadhat (Polgar and Prodmadhat 1971) study V.
Study I
The study population consisted of 28 patients, clinically diagnosed as suffering from
symptomatic COPD (ATS 1995), with an average smoking history of 52 pack-years
(range 20 to 103 pack-years) (Table 3). Two (7%) were former smokers, all of the oth-
ers current smokers. For inclusion in the study patients had to meet the following crite-
ria: 1) FEV1 before bronchodilator administration of less than 70% of the predicted
value (Viljanen 1982), 2) less than 10% reversibility from FEV1 before bronchodilator
administration in response to a short-acting β2-agonist (200 µg of Ventoline®‚ 0.1 mg,
GlaxoSmithKline, UK). Patients who were being treated for disease exacerbation or
who had needed antibiotic treatment for a respiratory-tract infection during the six
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weeks preceding the study were excluded. Four patients (14%) used inhaled steroids
(beclomethasone or budesonide, mean dose 900 µg/day, range 800 to 1200 µg/day)
and two (7%) took theophylline orally. None were on regular oral steroid treatment.
Five (18%) had been given a short-acting β2-agonist and three (11%) an anticholiner-
gic as rescue medication. None of the subjects used long-acting bronchodilators.
Two weeks before sputum induction, spirometry was undertaken and reversibility of
FEV1 assessed. Patients measured PEF every morning and evening for one to two weeks
before sputum induction. They also recorded daily symptoms (cough, sputum production,
shortness of breath) on a scale ranging from 0 to 4. Patients were allowed to continue
their usual medication for COPD except that short-acting bronchodilators were not al-
lowed during the four hours before induction.
Study II
Twenty-one patients with COPD took part in this prospective study. The FEV1 of each
before bronchodilator administration had to be less than 80% of the predicted value
(Quanjer et al. 1993) with less than 10% reversibility from FEV1 before bronchodilator
administration  in response to a short-acting β2-agonist (400 µg of salbutamol, Ventoline‚
0.1 mg). All of the patients were former smokers, who had stopped smoking at least one
year before entry into the study. They had smoked for a mean of 37.0 pack-years (range
20 to 60 pack-years). All except one of the patients were on inhaled steroid treatment
(beclomethasone or budesonide, < 1000 µg/day). The 16 healthy controls were selected
from hospital employees, had never smoked, and had normal pulmonary function. None
of the subjects had had a respiratory-tract infection within the four weeks preceding the
study.
Subjects visited the laboratory three times. During the first visit, subject characteris-
tics were documented and lung function (spirometry and diffusion capacity) measure-
ments were made. Subsequently, subjects underwent sputum induction, at the same time
of the day, on 2 days, 10 days apart. Results of spirometry were recorded before and after
the induction.
Study III
The study population consisted of 36 consecutive patients with respiratory symptoms
suggestive of asthma referred to the Outpatient Clinic of the Department of Allergy, Skin
and Allergy Hospital, Helsinki University Central Hospital during the period October
1996 to March 1997. Twenty-five patients who had been diagnosed as asthmatic during
the same period and 43 healthy individuals were recruited into control groups.
For inclusion in the study, patients with respiratory symptoms suggestive of asthma
had to be symptomatic at the time they were studied. We included only patients who had
reported at least two of six respiratory symptoms (cough, chest tightness with wheezing,
shortness of breath, sputum production, wheezing or cough on exercise, disturbed sleep)
for more than two months but not for more than one year. Each of the six symptoms was
graded on a scale ranging from 0 (asymptomatic) to 9 (most severe discomfort). Patients
who had been treated with anti-inflammatory asthma medication (corticosteroids, diso-
dium cromoglycate, nedocromil sodium or theophylline) or who had used H2-blockers
were excluded. Patients had to have normal chest and sinus X-rays, and normal serum C-
reactive protein values. The healthy subjects exhibited no respiratory symptoms and had
no history of chronic pulmonary disease. Patients or healthy subjects who had had a clin-
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ically diagnosed respiratory infection during the preceding eight weeks were excluded.
None of the smokers included had a history of chronic bronchitis (ATS 1995).
Patients were considered asthmatic in this study if they exhibited, during resting
flow-volume spirometry, an increase of 12% or more in FEV1 15 minutes after inhalation
of 200 µg of salbutamol (Buventol Easyhaler® 100 µg/dose, Orion Pharma, Espoo, Fin-
land), or if PEF varied by more than 12% between morning and evening on at least three
days during a two-week follow-up period. They also had to exhibit increased bronchial
responsiveness to inhaled histamine (Sovijärvi et al. 1993). Patients who did not display
significant airflow variability and were not hyperresponsive were diagnosed as exhibiting
respiratory symptoms. All of the healthy subjects had normal lung function.
Subjects visited the laboratory three times. During the first visit, subject characteris-
tics were documented and lung function measured. Patients measured PEF every morn-
ing and evening for one to two weeks. One week after the first visit, bronchial respon-
siveness to inhaled histamine was measured. A week later sputum was induced.
Follow-up
To study the effects of treatment with inhaled steroid and the course of respiratory symp-
toms, the 36 patients without variable airway obstruction were allotted at random to inhale,
on a single-blind basis, beclomethasone dipropionate (BDP), 400 µg b.i.d., from a multi-
dose powder inhaler (Beclomet Easyhaler® 200 µg/dose, Orion Pharma, Espoo, Finland), or
placebo (lactose) for the first three months. Randomisation was performed using a compu-
terised list based on a block size of 10. Compliance was checked by collecting the dry pow-
der inhalers after the three-month treatment period and checking whether they had been
used adequately. After the first three-month period patients were allowed to take sympto-
matic medication if needed (inhaled salbutamol, Buventol Easyhaler® 100 µg/dose). Symp-
toms, lung function, and blood and sputum samples were studied at three months and after
one year. Patients with asthma and normal subjects were not followed-up.
Study IV
The study population consisted of 60 children (five to 10 years of age) with newly diag-
nosed asthma, and 17 healthy control subjects (Table 3). The asthmatic children were
randomly selected from 180 subjects participating in a study of early pharmacological
treatment of childhood asthma (Turpeinen 2000). All of the asthmatic children had to
have a history of asthma symptoms, defined as cough, wheeze or decreased tolerance to
exercise, during the preceding month at least. They had to meet at least one of the follow-
ing inclusion criteria during the preceding month:
1) Abnormal diurnal variation in PEF (≥ 20%). Assessment of variation was based on
records in written diaries kept by the patient or the patient’s parents. Variation in PEF
was calculated by the investigator as 100 x (PEF evening - PEF morning)/ average PEF .
2) Bronchial reversibility of ≥ 15% as measured by PEF or FEV1 in response to 0.50 mg
of inhaled terbutaline (Bricanyl Turbuhaler® 0.25 mg/dose, AstraZeneca, London UK,
Sweden). 3) A fall of ≥ 15% in FEV1 during an exercise test conducted in accordance
with methods used at the clinic. Patients were excluded if they exhibited asthmatic symp-
toms only during the pollen season, if there was a history of passive smoking at home, or
if hairy pets had been kept at home during the previous months. They were also excluded
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if they had previously required maintenance treatment for asthma, had ever been treated
with inhaled corticosteroids for more than 60 days, or had had moderate to severe atopic
dermatitis (extent more than 15%). Before the study, patients were not allowed to have
been given an inhaled, nasal or oral corticosteroids, inhaled disodium cromoglycate or in-
haled nedocromil during the preceding two months, or a long-acting β2-agonist during
the preceding month. The healthy control subjects exhibited no respiratory symptoms and
had normal lung function. None of the children had had symptoms of a respiratory tract
infection within the four weeks preceding the study.
Cross-sectional study (baseline)
Patients and healthy controls were evaluated in relation to various baseline parameters
during a four-week run-in period. During this time all of the children paid three visits to
the outpatient unit. During the first visits, a physical examination was performed, and the
children and parents were interviewed. Flow-volume spirometry and skin-prick tests
were performed. The children were instructed about use of an electronic home spirome-
ter. Lung function and symptom scores were monitored twice daily at home throughout
the study. During the second visit, a histamine challenge test was performed. During the
third visit, at least one week after the second visit, flow-volume spirometry was under-
taken and sputum was induced, blood samples were taken, and data for baseline measure-
ments were downloaded from the home spirometer.
Longitudinal study (treatment)
After the baseline evaluation, children with asthma were randomised to three treatment
groups. In the double-blind study, children received 1) budesonide 400 µg b.i.d. for one
month (Pulmicort Turbuhaler 400 µg/dose, AstraZeneca), 200 µg b.i.d. for five months
(Pulmicort Turbuhaler 200 µg/dose), followed by 100 µg  b.i.d. for 12 months (Pulmi-
cort Turbuhaler 100 µg/dose) (n=19) or 2) the same treatment as the first group for the
first six months, thereafter placebo for 12 months (n=20). A third group of patients re-
ceived in an open study disodium cromoglycate 10 mg t.i.d. for 18 months (pressurised
metered dose inhaler with a valved spacer device, Lomudal with Fisonair, Fisons, UK)
(n=21). A patient in any treatment group who experienced an asthma exacerbation was
treated with budesonide, 400 µg b.i.d (Pulmicort Turbuhaler 400 µg/dose), for two
weeks, as a replacement for their normal treatment. Exacerbation of asthma was suspect-
ed if asthma symptoms were not controlled by up to six inhalations of terbutaline (Brica-
nyl Turbuhaler, 0.25 mg/dose, AstraZeneca) over 24 hours. In such cases, the patient
was examined at the clinic, where lung function measurements were performed. A deci-
sion about whether a patient needed treatment for an exacerbation was made by the in-
vestigator, who was blind in relation to budesonide treatment but not to cromoglycate
treatment. Compliance with dosing regimes was checked by recording peak inspiratory
flow by means of a Turbuhaler (PIFTBH) with a pneumotachograph, and by weighing re-
turned Lomudal canisters during each visit to the clinic. During the study period of 18
months, compliance with treatment instructions gradually declined in each group, from
90% to 55% (Turpeinen 2000).
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Study V
Eighty-two consecutive patients not known to suffer from asthma or any other chronic
respiratory disease were enrolled into the study in six health-care centres in the Helsinki
area of Finland, between November 1997 and February 1998. Each centre serves a popu-
lation of about 30 000. One physician from each centre participated into the study and
was specially trained in the Skin and Allergy Hospital, Helsinki University Central Hos-
pital. Patients complaining of coughing daily for more than one month were eligible for
enrolment into the study. Patients had to be symptomatic at the time they were studied
and were carefully questioned about respiratory symptoms other than cough. Patients be-
ing treated with anti-inflammatory asthma medication (corticosteroids, disodium cromo-
glycate, nedocromil sodium, theophylline, leukotriene antagonists) or who were using
angiotensin-converting-enzyme inhibitors were excluded. Patients who had suffered from
a respiratory infection during the preceding six weeks or who had symptoms of rhinitis
or gastro-oesophageal reflux were also excluded. Patients had to have normal chest and
sinus X-rays, and normal serum C-reactive protein values. Fifty-three healthy control
subjects with no history of asthma or other respiratory symptoms were recruited from the
staff of the Skin and Allergy Hospital, Helsinki University Central Hospital.
Physicians were asked to complete a questionnaire regarding the symptoms and med-
ical history of each patient. Participants were subjected to careful physical examination.
PEF values were recorded for all patients and control subjects (highest value from three
successful attempts in each case). If the physician suspected asthma on the basis of the
results of these examinations, variability of PEF values measured mornings and evenings
over a two-week period was recorded. When feasible, spirometry was performed. Sputum
was induced within a week of the consultation.
METHODS
Lung function measurements
Spirometry
Various spirometers were used (Studies I and IV Spirotrac III®, Vitalograph, Ltd., Buck-
ingham, UK;  study II Expirograph, Godart, Bilthoven, Netherlands; studies III and V
Medikro 905®, Medikro Oy, Kuopio, Finland). At least three forced expiratory volume
curves were obtained that were technically correct according to ATS acceptability criteria
(less than 5% variability, ATS 1987b) or ERS acceptability criteria (less than 4% variabil-
ity, Quanjer et al. 1993). Reference values were those of Viljanen (1982) in studies I, III
and V, European (Quanjer et al. 1993) in study II, and those of Polgal and Promadhat
(1971) in study IV. Reversibility of FEV1 as determined by means of spirometry was
measured in studies I, III and V 15 minutes after inhalation of 200 µg of salbutamol
(Ventoline MDI with Volumatic or Buventol Easyhaler).
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Diffusing capacity
Single breath carbon monoxide diffusing capacity (DLCO/VA) was measured (Master-
screen PFT®, Erich Jaeger BmbH, Hoechberg, Germany) as described (ATS 1987c) in
study II.
Histamine challenge
Airway responsiveness to histamine, expressed as the histamine dose (mg) resulting in a
15% decrease in FEV1 (PD15 FEV1) or a 20% decrease in PEF (PD20PEF), was deter-
mined using an automated, inhalation-synchronised, dosimetric jet nebulizer (Spira Elec-
tro 2®, Respiratory Care Centre, Hämeenlinna, Finland) as previously described (Sovi-
järvi et al. 1993, Pelkonen et al. 1997). The maximum dose inhaled histamine was 1.6
mg. PD15 FEV1 >1.6 mg of histamine is considered normal for adults and PD20 PEF >1.6
mg of histamine for children.
Peak expiratory flow (PEF)
PEF values were measured at home every morning and evening by means of a Mini
Wright peak-flow meter (Clement Clarke Int., London, UK) over a two-week follow-up
period (studies I, III to V). Three measurements were made and the highest value was re-
corded. Variation in PEF was calculated by the investigator using the formula 100 x (PEF
evening - PEF morning) / average PEF evening and morning.
Home recordings
In study IV, lung function was recorded at home using a Vitalograph Data Storage Spirome-
ter (Vitalograph) specially designed for long-term recording and storage of lung-function
parameters, as previously described (Pelkonen et al. 1997 and 2000). The device consists of
a pneumotachograph with a built-in electronic diary. Lung function parameters, including
FVC (forced vital capacity), FEV1, PEF and PIFTBH were monitored twice daily. Measure-
ment was repeated up to five times, until the two best sets of values met ATS (1995) repro-
ducibility criteria. Children were asked to record symptom scores twice daily (scales 0 to
10) and use of rescue medication (Bricanyl Turbuhaler 0.25 mg/dose). The median PIFTBH
during the last run-in week had to be at least 40 l/min as measured and recorded using a Vi-
talograph Data Storage Spirometer and judged by the investigator.
Skin prick tests
Skin prick tests were made using 10 common inhalant allergens (Soluprick SQ, 10 HEP,
ALK, Denmark), and positive (histamine dihydrochloride, 10 mg/ml) and negative (sol-
vent) control solutions. The allergens used were birch, timothy, meadow fescue, and
mugwort pollen; horse, cat, dog and cow danders; the mite Dermatophagoides pteronys-
simus; and spores of the mould Cladosporium herbarum. A subject was classified as at-
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opic if any allergen caused a weal 3 mm or more in diameter and the control solutions
produced the expected results (Dreborg 1989).
Sputum induction
Various ultrasonic nebulizers and different concentrations of saline were used for sputum
induction (Table 4). Before induction, subjects were asked to blow their noses and rinse
their mouths. Pre-treatment with a bronchodilator was used in four of the five studies
(Table 4). Lung function was monitored by means of FEV1 or PEF before and after in-
duction in all studies except study I.
In study I, 10 minutes after bronchodilator pre-treatment, spirometry was undertaken.
If FEV1 after bronchodilator administration was less than 1 l, normal (0.9%) saline was
used, and FEV1 was checked every three minutes. If FEV1 after bronchodilator adminis-
tration was more than 1 l, induction was started with 3% hypertonic saline, and FEV1 was
measured every seven minutes. Inhalation was discontinued if lung function fell by more
than 20% or if troublesome symptoms occurred.
Patients were urged to interrupt inhalation repeatedly to cough sputum into a sterile
plastic cup. To minimise salivary contamination, saliva was collected in a separate cup in
study IV (Gershman et al. 1996). Inhalation times in studies III to V were 15 to 20 min-
utes. In studies I and II they varied from two to 21 minutes.
Sputum processing
Various sputum-processing methods were used (Table 5). The methods were modified
from those described by Pin et al. (1992a) and Fahy et al. (1993a) and validated by Pizzi-
chini et al. (1996a) and in´t Veen et al. (1996).
Studies I and III
The method of sputum examination described by Pizzichini et al. (1996) was used. Brief-
ly, all sputum macroscopically free of salivary contamination was selected and treated
with dithiothreitol (Sputolysin, Boehringer-Calbiochem Corp., LaJolla, Ca, US, diluted
10-fold in distilled water). The mixture was incubated for 15 minutes on a roller mixer at
room temperature. An equal volume of phosphate-buffered saline (PBS) was added and
incubation was continued for a further five minutes. The mixture was filtered using a 52-
µm mesh nylon filter (Nybolt PA-53/35, Seidengaze, Germany). Sputum cells were sepa-
rated by centrifugation at 800 g for 10 minutes and sputum supernatant was collected for
determinations of fluid-phase markers. Cells obtained after centrifugation were resus-
pended in 1 ml of PBS and total cell numbers were determined using a haemocytometer.
Viability was measured using the trypan-blue (Sigma Chemical, St.Louis, MO, US) ex-
clusion test. The cell suspension was cytocentrifuged (Cytospin 3®, Shandon, Astmoor,
UK) on to Vectabond-treated (Vectabond® Reagent, Vector Laboratories Inc., CA, US)
microscope slides at 300 rpm for five minutes. Slides were air-dried for at least 30 min-
utes. One slide was used for differential staining by means of the May-Grünwald-Giemsa
(MGG) method. Two slides were fixed using Carnoy’s fixative and stained using toluid-
ine blue (Fluka AG, Buchs, Switzerland) for detection of metachromatic cells (basophils,
mast cells). At least 400 nonsquamous cells were counted on MGG-stained slides, 1500
on toluidine blue-stained slides, using a standard light microscope  (Axioskop 20, Carl
Zeiss, Heidenheim, Germany).
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Table 5. Sputum processing
Study I Study II Study III Study IV Study V
Plugs selected Plugs selected Plugs selected Whole sample Plugs selected,
smears made
frozen and thawed
↓ ↓ ↓ ↓ ↓
Four times volume of 1 ml 10% DTT Four times volume of Four times volume of Four times volume of
10% DTT 10% DTT 10% DTT 10% DTT
↓ ↓ ↓ ↓  ↓
15 minutes of Five minutes of 15 minutes of 15 minutes of 15 minutes of
incubation  incubation incubation incubation incubation
↓ vortex ↓ ↓ ↓
Four times volume of Aspiration through Four times volume Four times volume Five times volume
PBS  21G needle of PBS of PBS of CTAB
vortex
↓ ↓ ↓ ↓ ↓
Five minutes of Five minutes Five minutes One hour of
incubation of incubation of incubation incubation
↓ ↓ ↓ ↓ ↓
Filtration through Filtration through Filtration through Filtration through
52 µm gauze 52 µm gauze 52 µm gauze 52 µm gauze
↓ ↓ ↓ ↓ ↓
Centrifugation Centrifugation Centrifugation Centrifugation Centrifugation
800 g, 10 minutes 450 g, 10 minutes 800 g, 10 minutes 800 g, 10 minutes 800 g, 10 minutes
↓ ↓ ↓ ↓ ↓
Aspiration of Aspiration of Aspiration of Aspiration of Aspiration of
supernatant supernatant supernatant supernatant supernatant
↓ ↓ ↓ ↓
Resuspension in PBS Resuspension in PBS Resuspension in PBS Resuspension in PBS
↓ ↓ ↓ ↓
Preparation of Preparation of Preparation of Preparation of
cytospins cytospins cytospins cytospins
300 rpm, five minutes 450 rpm, six minutes 300 rpm, five minutes 300 rpm, five minutes
DTT = dithiotreitol (Sputolysin, CalbioChem, La Jolla, CA, US), CTAB = cetyl-N,N,N-trimethylammonium bromide
Study II
Sputum was analysed as described by Pin et al. (1992a), with slight modifications. Sputum
plugs (total weights 70 to 200 mg) were transferred into an Eppendorf tube and 1 ml of a
10% solution of the mucolytic agent dithiothreitol (Sputolysin) was added. The sample
was rapidly mixed for two minutes, aspirated and expelled through a 21 G needle five
times, and mixed for a further 30 seconds. The cell suspension was filtered through a 52-µm
gauze and its weight was recorded. The sample was spun for 10 minutes at 450 g at 25°C.
The cell pellet was resuspended in 0.01 PBS, pH 7.2, containing 2% of bovine serum albu-
min (Behringwerke AG, Marburg, Germany) and the cells were counted by means of a
haemocytometer. Viability was determined by means of trypan blue exclusion.
Cytocentrifuge preparations were made by adding 75-µl portions of a cell suspension
(0.75 x 106cells/ml) to Shandon II cytocentrifuge cups and centrifuging for six minutes at
450 rpm. Two slides were stained with Wright-Giemsa stain (BDH, Poole, UK) and ex-
amined by light microscopy to allow differential counting. Slides were coded and count-
ed blind by two investigators. Four hundred nucleated cells were counted. To identify
metachromatic cells two slides were stained with toluidine blue and 600 nucleated cells
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per slide were counted. The remaining slides were kept at -80°C for further immunocyto-
chemical staining.
Immunocytochemical analysis
Cell surface markers were demonstrated by immunocytochemical staining with the
monoclonal mouse antibodies CD3 (all T cells), CD4 (helper T cells), CD8 (suppresser T
cells), CD 20 (all B cells), CD25 (activated T cells), CD 45 (all leukocytes), CD 68 (mac-
rophages), and Ber-Mac3 (activated macrophages) (all from Dako, Dakopatts, Copenha-
gen, Denmark) using the alkaline phosphatase anti-alkaline phosphatase (APAAP) meth-
od in accordance with the suppliers’ instructions (Cordell et al. 1984). Briefly, slides
bearing frozen cells were thawed and fixed with 4% paraformaldehyde, pH 7.2, for five
minutes at room temperature. After fixation, preparations were rinsed with 0.05 M TRIS-
buffered saline, pH 7.35, (TBS) and incubated with primary antibody diluted in TBS
(1:100 for all antibodies expect 1:50 for CD20) in a moist chamber at room temperature
for 30 minutes. Secondary rabbit anti-mouse antibody and mouse APAAP complex (both
from Dako) diluted 1/25 in TBS were applied to slides for 30 minutes in each case. Addi-
tional incubations of secondary antibody and APAAP-complex were then undertaken for
10 minutes. Washing between steps was done with TBS. Endogenous alkaline phos-
phatase activity was blocked with levamisole and the signal was developed with Fast Red
Violet substrate for 20 minutes, giving an intense red coloration. The substrate was pre-
pared from 0.2 M TRIS/HCL-buffer, pH 8.5, 25 ml; distilled water 15 ml; levamisole 15
mg; naphthol AS-BI phosphate 5 mg; dimethylformamide 0.5 ml, and Fast Red Violet 40
mg (all from Sigma Chemical, St. Louis, MO, US). Mayer’s haematoxylin (Sigma Chem-
ical) was used for counterstaining, and the slides were mounted with a water-based
mounting medium (Glycergel, Dako). Four hundred nucleated cells were counted using
bright-field microscopy. Positive cells were expressed as percentages of intact, round, nu-
cleated cells, ignoring squamous epithelial cells. Mouse IgG1 (Dako) was used as a nega-
tive control in all of the experiments. Cytocentrifuge preparations made from peripheral
blood leukocytes separated using a Ficoll-Paque (Pharmacia, New Jersey, US) gradient
were used as positive controls. For anti-CD25 staining positive controls, leukocytes were
stimulated with phytohaemagglutinin in culture for 48 hours.
Study IV
We used a sputum processing method modified from the one described by Fahy and col-
leagues (Fahy et al. 1993) and validated by in´t Veen et al. (1996). Briefly, an entire spu-
tum sample was weighted and treated with an equal volume of dithiothreitol (Sputolysin
10%, Calbiochem Corp.) and PBS. The samples were gently mixed and incubated in a
shaker at room temperature. The resulting suspension was centrifuged at 800 g for 10
minutes, and the supernatant was aspirated and stored in Eppendorf tubes at -200C for
later assay. The cell pellet was resuspended, and viabilities and absolute numbers of cells
per milligram of sputum processed were calculated by means of trypan-blue exclusion,
using a haemocytometer. Coded cytospins were prepared and stained using MGG stain
and toluidine blue, to obtain differential cell counts. Four hundred nonsquamous cells
were counted on the MGG-stained slides, 1500 cells on toluidine-blue-stained slides. A
sputum sample was considered adequate if it had less than 80% of squamous epithelial
cell contamination from saliva (in´t Veen et al. 1996).
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Study V
Sputum handling in primary health care
Sputum samples were transferred to Petri dishes and examined against a dark surface.
The more viscous parts were collected, using forceps, and mixed. Some of each sample
was used to make two smears, which were air-dried. The rest was transferred into a pre-
weighed tube and frozen at –20 °C.
Sputum analysis in the laboratory
Frozen sputum samples and air-dried slides were sent to the Skin and Allergy Hospital,
where further analyses were undertaken. Samples were processed using the method pre-
viously described and validated (Metso et al. 2001). Briefly, each sample was thawed and
treated with a DTT (diluted 10-fold with distilled water) and a detergent (0.5% cetyl-
N,N,N-trimethylammonium bromide, 0.4% human serum albumin, 100 mM PBS, pH
7.2). After incubation for one hour cells were lysed, and markers inside and outside the
cells released and solubilized. Sputum supernatant was separated from cell debris by cen-
trifugation and frozen at -200C for later assay.
Air-dried slides were stained using eosin and methylene blue. Cell proportions were
assessed semi-quantitatively, on a scale from 0 to 4, modified from previously described
scales (O´Connell et al. 1978). Eosinophils were graded as 0 = none or occasional, 1 =
scanty, 2 = moderate, 3 = numerous, or 4 = predominant. The approximate values of the
grades were 0 = eosinophils fewer than 1% of all non-squamous cells, 1 = eosinophils
one to 5% of all non-squamous cells, 2 = eosinophils five to 10% of all non-squamous
cells, 3 = eosinophils 10 to 50% of all non-squamous cells, and 4 = eosinophils more
than 50% of all non-squamous cells. A sample was considered adequate and originating
from the lower airways if it contained macrophages and fewer than 50% of squamous ep-
ithelial cells.
Fluid-phase measurements
Concentrations (µg/l) in thawed serum and sputum supernatants of two markers of eosi-
nophil activation, eosinophil cationic protein (ECP) and eosinophil peroxidase (EPO),
and of two markers of neutrophil activation, myeloperoxidase (MPO) and human neu-
trophil lipocalin (HNL), were measured. ECP and MPO concentrations were determined
using commercially available immunoassay kits (Pharmacia). EPO and HNL concentra-
tions were determined using prototype kits (Pharmacia CAP System FEIA, Pharmacia)
as previously described (Helenius et al. 1998). All analyses were blind in relation to clin-
ical characteristics of subjects.
Statistical analyses
Data are expressed as means plus or minus the standard error of the mean (SEM), medi-
ans or ranges. In the case of bronchial responsiveness following histamine challenge, ge-
ometric means were calculated. Significances of differences between several groups were
assessed using Kruskal-Wallis one-way analysis by ranks. Significances of differences
between two groups were assessed using the Mann-Whitney U-test or the χ2-test, as ap-
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propriate. Wilcoxon´s test relating to paired data was used in determining significances
of differences for follow-up data relating to a given patient. Significances of correlations
were assessed using Spearman´s test. Two-tailed p values below 0.05 were considered to
indicate significance.
The reference (normal) range for sputum eosinophils in study III was calculated as
three standard deviations of mean values for the healthy control group. The control group
was used to establish upper limits of normal ranges (90th percentiles) for sputum ECP,
EPO, MPO and HNL values in study V and for numbers of eosinophils in blood and spu-
tum in study IV.
In study IV, sensitivities and specificities of results of determinations of numbers of
eosinophils in blood and sputum in relation to diagnoses of asthma were assessed, using
cut-off values relating to the healthy control group. However, since the cut-off values
were selected arbitrarily (Pizzichini et al. 1997b), the reliability of determinations of
numbers of blood and sputum eosinophils was assessed by preparing a receiver-operat-
ing-characteristic (ROC) curve for each test (Hanley and McNeil 1982). Areas under
curves (AUCs) were compared using the method of Hanley and McNeil (1983). AUCs
closest to 1.0 indicate greatest reliability of diagnosis.
The reproducibility of sputum cell counts was examined by means of repeated-
measures analysis of variance with calculation of an intraclass correlation coefficient (the
ratio of the variance of cell counts between subjects to the total variance in cell counts,
including observer and error variance) (Kramer and Feinstein 1981). Values above 0.75
indicate high reliability. Intrapatient variability at various time points was also assessed,
using a coefficient of reproducibility representing limits within which 95% of the differ-
ences are expected to be found (Bland and Altman 1986).
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RESULTS
CLINICAL CHARACTERISTICS OF SUBJECTS
Baseline clinical characteristics of subjects are shown in Table 3. Most patients with
COPD were male. There were more women than men in the other groups of adults.
COPD patients were older than other adult subjects (p < 0.0001). Subjects were regarded
as atopic if at least one result of skin-prick testing was positive (see Methods). Numbers
and percentages of atopic subjects are shown in Table 3.
Reversibility of lung-function measurements and airway
responsiveness
Results of lung-function measurements at baseline from all studies are shown in Table 3.
Results of reversibility testing, PEF follow-up and histamine challenge in studies I, III
and IV are shown in Table 6.
In study II, mean diffusion capacity was 62 ± 3.4% of that predicted. In study V in
primary care, 13 of 82 patients (16%) were diagnosed as suffering from asthma on the
basis that PEF values varied by more than 20% between morning and evening on three
days during the two-week follow-up period, or that reversibility of FEV1 exceeded 15%.
In the asthmatic children in study IV, PD20PEF correlated with baseline FEV1 (r =
0.43, p = 0.001), morning PEF (% of predicted) (r = 0.39, p = 0.01), and evening PEF (%
of predicted) (r = 0.40, p = 0.01). Atopic asthmatic children were more responsive to his-
tamine than non-atopic asthmatic children (PD20PEF 0.84 ± 0.10 versus 1.21 ± 0.10 mg,
p = 0.009). These two subgroups of asthmatics did not differ from each other in respect
of other lung function measurements.
Table 6. Bronchodilator responses, PEF-variability and airway responsiveness at baseline in stu-
dies I, III and IV
Studies and Diagnoses Reversibility of Variability of PEF Airway responsiveness
FEV1 (%)  (%) mg*
Study I
COPD (n = 28) 2.5 (-7.4 - 9.9) 8.9 (1.9 - 39) nd
Study III
Respiratory symptoms (n = 36) 2.5 (0 - 6.0) 5.2 (0 - 11) > 1.6
Asthma (n = 25) 11.2 (11 - 60) 21.1 (11 - 60) 0.40 (0.02 - 1.25)
Healthy controls (n = 43) nd nd > 1.6
Study IV
Asthma (n = 60) nd 10.4 (3.1 - 25) 0.92 (0.02 - 1.6)
Healthy controls (n = 17) nd 0.3 (0 - 1) 1.50 (0.41 - 1.6)
Data expressed as means and ranges,  nd = not determined
* In study III PD15 is the dose of histamine provoking a 15% fall in FEV1. In study IV PD20, is the dose of
histamine provoking a 20% fall in PEF (Sovijärvi et al. 1993)
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Symptoms
Different questionnaires and scales relating to symptoms were used in each study. Re-
sults are therefore not comparable between studies. In study III, patients with asthma had
higher total symptom scores (p = 0.005) than patients with respiratory symptoms sugges-
tive of asthma. They also had higher individual scores relating to wheezing (p < 0.0001),
shortness of breath (p = 0.006), and exercise symptoms (p = 0.0003). Duration of symp-
toms was similar in both groups (mean nine months).
In study IV, at baseline 23 asthmatic children (38%) complained only of cough. Thir-
ty-seven (62%) had experienced both coughing and wheezing. Children who wheezed
were significantly more hyperresponsive to histamine than children who did not
(PD20PEF of 1.23 ± 0.10 versus 0.84 ± 0.01 mg, p = 0.009). Children who wheezed also
had more sputum eosinophils than those with just cough (7.8 ± 2.0 versus 1.2 ± 0.5 %,
p = 0.02). The mean duration of symptoms for all asthmatic children was 10 months
(range one to 72 months). The three treatment groups in study IV did not differ from
each other at baseline.
In study V, the mean duration of cough in primary health care patients was 11
months (range one to 96 months). It was 15 months for asthmatics, and 10 months for
other patients. Forty patients (49%) reported marked sputum production, 38 (46%)
wheezing or cough on exercise, 30 (37%) disturbed sleep, 28 (34%) shortness of breath,
and 23 (28%) chest tightness with wheezing. Asthmatics more often experienced sputum
production (p = 0.03, χ2-test), and chest tightness with wheezing (p = 0.04) than patients
with prolonged cough without asthma.
Measurements relating to blood and serum
In study III, asthma patients had significantly higher blood eosinophil counts and higher
concentrations of serum EPO than patients with respiratory symptoms (p = 0.002, p =
0.008), and healthy individuals (p < 0.0001 in both cases) (Table 7). Patients with respi-
ratory symptoms also had higher blood eosinophil counts and higher concentrations of
serum EPO than healthy individuals (p = 0.01, p = 0.02, respectively). Atopic asthmatics
had higher blood eosinophil counts than non-atopic asthmatics (0.51 versus 0.27 x 109/l,
p = 0.04). In study V, serum ECP was highest (mean 12.0 mmg/l, range 4-26 mmg/l) in
patients with chronic cough who had been diagnosed as suffering from asthma.
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Table 7. Measurements relating to blood and serum.
Studies and Diagnoses Blood eosinophil Serum Serum Serum Serum
counts (x 109/l) ECP EPO MPO HNL
(µg/l) (µg/l) (µg/l) (µg/l)
Study III
Respiratory symptoms (n = 36) 0.17 (0 - 0.61) 11.8 (3.5 - 39) 13.8 (1.3 - 50) 254 (167 - 555) 112 (44 - 293)
Asthma (n = 25) 0.41 (0.66 - 1.0) 15.2 (3.3 - 50) 30.0 (2.3 - 111) 251 (155 - 535) 104 (54 - 171)
Healthy controls (n = 43) 0.11 (0.02 - 0.27) 8.1 (1.0 - 18) 10.6 (1.2 - 81) 200 (145 - 283)94.5 (56 - 139)
p-value < 0.0001 = 0.003 < 0.0001 ns ns
Study IV nd nd nd nd
Asthma (n = 60) 0.51 (0.02 - 3.54)
Healthy controls (n = 17) 0.17 (0.03 - 0.36)
p-value =0.0028
Study V
Prolonged cough (n = 82) nd 10.5 (2-71) nd nd nd
Healthy controls (n = 53) 6.7 (2-17)
p-value = 0.01
Data are expressed as means and ranges. P-values relate to between-group comparisons in each study
(Kruskall-Wallis), ns = not significant, nd = not determined
INDUCED SPUTUM
Safety of sputum induction
Sputum induction procedure was well tolerated in all studies. One child in study IV re-
ported nausea but otherwise there were no notable side effects. The mean changes in lung
function, and ranges, are shown in Table 4.
COPD
Studies I and II related to COPD patients. In both studies, a fairly high-output nebulizer,
the DeVilbiss Ultra-neb, was used. In study II, spirometry was performed before and af-
ter induction in 16 of 21 patients. After pre-treatment and induction, there was an in-
crease in FEV1 (p = 0.007) (Table 4). Study I was specifically designed to study the safe-
ty of sputum induction. The mean change during induction from FEV1 before bronchodi-
lator treatment was -162 ml (-541 to 205 ml), i.e. -8.5% (-23 to 11%) (p = 0.001). The
mean change during induction from FEV1 after bronchodilator treatment was -202 ml
(-625 to 95 ml), i.e. -10.7% (-25 to -5%) (p < 0.0001). In three subjects (11%) the fall in
FEV1 from baseline before bronchodilator treatment was more than 20%. In a further 10
(36%) it was between 10 and 20%. All patients in whom the fall in FEV1 was 20% or
more were followed-up carefully and treated with salbutamol by inhalation. A statistical-
ly significant inverse relationship existed between reversibility in FEV1 and fall in FEV1
during induction (r = -0.4, p = 0.03). Otherwise, no correlation was found between levels
of inflammatory markers in sputum, baseline clinical characteristics and changes in FEV1
during induction. No significant differences were found in relation to any parameter be-
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tween female and male subjects, or between patients on inhaled steroids and steroid-na-
ive patients. Three female patients (11%) had FEV1 values after bronchodilator treatment
of less than 1 l (mean 0.87 l, range 0.81 to 0.94 l, on average 36% of predicted values,
range 34 to 38%), and sputum was induced in these patients using only 0.9% saline.
Mean changes in FEV1 in these patients were -60 ml (-118 to 53 ml), i.e. -7.2% (-15 to
7%) from baseline before bronchodilator treatment and -120 ml (-188 to 17 ml), i.e.
-13.7% (-20 to 2%) from baseline after bronchodilator treatment.
Asthma
Studies III to V involved patients with asthma (Table 4). Two types of low-output ultra-
sonic nebulizers were used, the Omron U1 and Spira Ultra. In study III, there was no
pre-treatment. Asthma patients exhibited small but statistically significant (p = 0.007)
falls in PEF values during induction. In studies IV and V, pre-treatment was undertaken.
No significant fall in PEF values was noted. In study IV, there were weak correlations be-
tween percentage change in PEF during sputum induction and mean PEF (% of predict-
ed) as recorded by patients at home (r = -0.32, p = 0.03) and variability between morning
and evening PEF values (r = 0.35, p = 0.01).
Respiratory symptoms suggestive of  asthma, chronic cough, and healthy
controls
Study III involved patients with respiratory symptoms suggestive of asthma. The low-
output nebulizer Spira Ultra was used, with no pre-treatment. Like the patients with
asthma proper, patients with respiratory symptoms suggestive of asthma exhibited a
small but statistically significant fall in PEF during induction (p = 0.005). In study V, pa-
tients with chronic cough exhibited no fall in PEF values (Table 4). Healthy controls
were included in all but study II. All three types of ultrasonic nebulizer were used. No
significant fall in lung function was observed (Table 4).
Success of sputum induction
In studies I, II, III and IV, a sputum sample was considered adequate if squamous epithe-
lial cell contamination was less than 80% on MGG-stained cytospin slides (in‘t Veen et
al. 1996). In study V smears were examined. A sample was considered adequate and
originating from the lower airways if it contained macrophages and fewer than 50% of
squamous epithelial cells. Overall, sputum induction at baseline was successful in 82%
of cases. Success rates in individual studies and for different patient groups at baseline
are shown in Table 4. In study III, the success rate in patients with respiratory symptoms
after three months of treatment was 87%. After one year it was 81%. In study IV, the suc-
cess rate in relation to five-year old children was 67%. It was 75% for six-year old chil-
dren, 86% for children from seven to 10 years of age, and 100% for children over 10
years of age. After six months of treatment it was 68%, after 18 months 60%. There was
no significant correlation between age and extent of squamous epithelial cell contamina-
tion, and there were no significant differences between boys and girls. Success rates did
not differ significantly between different types of nebulizer.
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Sputum total and differential cell counts at baseline
Various methods of sputum induction and processing of sputum were used, making com-
parisons between studies difficult. In study II, patients with COPD had higher total cell
counts (mean 9.5 103/mg, range 1.4 to 84 103/mg) than healthy controls (p < 0.002), and
higher percentages of neutrophils (mean 81.3, range 19 to 24) (p < 0.001), and lower per-
centages of macrophages (mean 17.8, range 6.5 to 65) (p < 0.001). The median percent-
age of eosinophils in COPD patients was 0.25 (range 0 to 33).
Sputum was induced using different types of nebulizer in studies I and III. The meth-
ods of sputum processing were, however, similar. Total and differential cell counts in
studies I and III are shown in Table 8 and Figure 3. Patients with respiratory symptoms
exhibited highest total cell counts (p = 0.02 in relation to comparison with asthma pa-
tients, p = 0.0009 in relation to comparison with COPD patients, and p = 0.0008 in rela-
tion to comparison with healthy controls). Eosinophil counts were highest in asthma pa-
tients (p = 0.01 in relation to comparison with respiratory-symptom patients, p < 0.0001
in relation to comparison with healthy controls). COPD patients did not differ signifi-
cantly from asthmatics in relation to sputum eosinophil counts but sputum eosinophil
counts were higher than in patients with respiratory symptoms (p = 0.04) and healthy
controls (p < 0.0001). Patients with respiratory symptoms also had higher sputum eosi-
nophil counts than healthy controls (p < 0.0001). Sputum neutrophil counts were highest
in COPD patients (p = 0.03 in relation to comparison with asthma patients, p = 0.004 in
relation to comparison with respiratory-symptom patients, and p < 0.0001 in relation to
comparison with healthy controls). Sputum macrophage counts were highest in healthy
controls (Table 8). Metachromatic cell counts were highest in asthma (p = 0.04 in rela-
tion to comparison with respiratory symptoms, p = 0.01 in relation to comparison with
healthy controls). However, COPD patients also exhibited higher metachromatic cell
counts than patients with respiratory symptoms (p = 0.04) and healthy controls (p =
0.0007). Differential cell counts showed that COPD subjects in study I had higher spu-
tum eosinophil counts (p = 0.01) and macrophage counts (p = 0.0002) and lower neu-
trophil counts (p = 0.01) than COPD patients in study II.
Total and differential cell counts in sputum at baseline in study IV are shown in Ta-
ble 8 and Figure 4. Asthmatic children had higher sputum eosinophil counts and sputum
metachromatic cell counts than healthy children. Atopic asthmatics had higher sputum
eosinophil counts (p < 0.0001) than non-atopic asthmatics. No differences were seen be-
tween atopic and non-atopic healthy children, or between the three kinds of treatment at
baseline. Children who wheezed had significantly higher sputum eosinophil counts than
those with just cough (mean 2.8%, range 0 to 39%, versus mean 0.4%, range 0 to 5.6%,
p = 0.02). Cell viability, as assessed by means of trypan-blue exclusion, always exceeded
70%.
In study V, a semiquantitative scale relating to sputum eosinophil numbers was used
(Table 9). The score relating to sputum eosinophils was higher in patients with chronic
cough than in healthy subjects (p = 0.001). No healthy subject had a sputum-eosinophil
score greater than 1 (5% eosinophils). A sample was defined as positive for eosinophils if
the score relating to eosinophils was 2, 3 or 4. Using this criterion, 14 patients with pro-
longed cough (19%) had eosinophil-positive sputum samples. Five of these 14 patients
(36%) were diagnosed as having asthma, while nine of the 14 patients (64%) were not.
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Figure 3. Sputum eosinophils in the four adult patient groups (studies I and III). Horizontal lines
represent mean values (p < 0.0001).
Figure 4. Sputum eosinophils in children (study IV). Horizontal lines represent mean values
 (p = 0.0001).
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Table 9. Measurements relating to induced sputum in study V
Prolonged cough Healthy persons
(n = 82) (n = 53)
Sputum
Weight, mg 290 (10 - 2980) 110 (3 - 913)
Eosinophils *
0 - 1 59 (81%) 49 (100%)
2 7 (10%) 0 (0%)
3 4 (5%) 0 (0%)
4 3 (4%) 0 (0%)
ECP (µg/L) † 1015 (44 - 65062) 498 (68 - 2706)
EPO (µg/L) ‡ 297 (55 - 33408) 63 (25 - 6830)
MPO (µg/L) 93 (80 - 34300) 138 (80 - 1524)
HNL (mg/L) 7.3 (0.5 - 98) 5.4 (1.1 - 19)
Data are expressed as medians and ranges or numbers and percentages (in the case of eosinophils).
Sputum samples were obtained from 73 patients with chronic cough and 49 healthy subjects.
* Semi-quantitatively, on a scale from 0 to 4, p = 0.001 (χ2-test)
† p = 0.02 (Mann-Whitney U-test), ‡ p = 0.005 (Mann-Whitney U-test)
Reproducibility of sputum cell counts
Reproducibility of sputum cell counts was examined in studies II and III. In patients with
COPD, reproducibility was high for the main types of cells, neutrophils and macrophag-
es, both on a within investigator basis (PR) (r = 0.99 for neutrophils, r = 0.99 for macro-
phages) and between investigators (PR and JK) (r = 0.95 for neutrophils, r = 0.77 for
macrophages). Reproducibility was lower for other cell types, both on a within investiga-
tor basis (r = 0.33 for lymphocytes, r = 0.30 for eosinophils) and between investigators (r
= 0.16 for lymphocytes, r = 0.16 for eosinophils).  To allow assessment of within-subject
variability, differential cell counts in two sputum samples, induced 10 days apart, were
compared. Reproducibility was high for major cell types (r = 0.84 for neutrophils, r =
0.67 for macrophages, r = 0.90 for eosinophils), but lower for lymphocytes (r = 0.30) and
total cell count (r = 0.13). In patients with asthma (study III, data not shown in manu-
script) within-investigator reproducibility (PR) (r = 0.93 for neutrophils, r = 0.92 for
macrophages, r = 0.89 for lymphocytes, r = 0.98 for eosinophils, r = 0.94 for bronchial
epithelial cells, r = 0.85 for squamous cells) and between-investigator reproducibility (PR
and TM) (r = 0.86 for neutrophils, r = 0.44 for macrophages, r = 0.34 for lymphocytes, r
= 0.81 for eosinophils, r = 0.9469 for bronchial epithelial cells, r = 0.98 for squamous
cells) were assessed.
Immunocytochemical analysis
In an attempt to characterise further the inflammatory nature of COPD, good quality cyt-
ospin preparations from both COPD patients (n = 8) and healthy controls (n = 8) were stud-
ied by means of immunocytochemistry. Very few CD3+, CD4+, and CD8+ and no CD20+
or CD25+ cells were found (Table 10). The percentage of CD45+ cells was significantly
higher in COPD patients (Table 10) than in healthy subjects. In both groups, most macro-
phages (stained for CD68) were activated, as indicated by positive staining with Ber-Mac3.
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Table 10. Cell-surface markers in induced sputum in study II.
Parameter COPD patients Healthy subjects
CD3 (%) 1.8 ± 0.7 2.1 ± 0.5
CD4 (%) 0.1 ± 0.1 2.1 ± 0.2
CD8 (%) 0.3 ± 0.1 0.4 ± 0.2
CD45 (%)* 80.5 ± 5.5 52.6 ± 6.1
CD68(%)* 17.9 ± 4.8 71.2 ± 4.5
Ber-Mac3 (%) 10.1 ± 2.2 47.4 ± 7.4
Ber-Mac3/CD68 56 66
Values are expressed as means ± SEMs, n = 8 for both groups, calculated as percentages of non-squamous
cells. Percentages of activated macrophages are expressed in relation to total numbers of macrophages.
* p < 0.05 Mann-Whitney U-test
Sputum fluid-phase measurements
Results of fluid-phase measurements in studies I and III are shown in Table 8. ECP values
were highest in asthma patients (p = 0.002 in comparison with healthy controls). COPD pa-
tients also had high ECP values (p < 0.0001 in comparison with healthy controls). Both
asthmatics and patients with respiratory symptoms had higher sputum EPO levels than
healthy controls (p < 0.0001) but they did not differ significantly from each other. MPO val-
ues were highest in COPD patients (p < 0.0001 in comparison with all other groups).
In study V, sputum EPO and ECP levels were higher in patients with prolonged
cough than in healthy subjects (Table 9). Values for the sputum neutrophil markers MPO
and HNL were not significantly different between patients and controls. There were no
significant differences in levels of inflammatory markers between smokers and non-
smokers or atopic and non-atopic subjects in any group. If smokers were excluded from
the analysis differences were essentially unaffected.
Normal values for inflammatory markers: sensitivity and specificity
In study III, the normal upper limit (mean + 3 SD) for percentage of sputum eosinophils
(0.7) was calculated on the basis of values in sputum from healthy subjects. Fourteen
asthma patients (67%) who produced samples for sputum analysis exhibited high per-
centages of sputum eosinophils, as opposed to 13 patients with respiratory symptoms
(38%) and one healthy subject (3%). Receiver operating characteristic curves for percent-
ages of eosinophils, and ECP and EPO levels in sputum and blood were examined. Areas
under curves relating to each test revealed that percentage of sputum eosinophils (AUC
0.88) was the most sensitive and specific marker in the case of asthmatics. AUCs for oth-
er markers were Ex-EPO 0.87, B-eos 0.84, S-EPO 0.83, S-ECP 0.76, and Ex-ECP 0.75.
In patients with respiratory symptoms the best marker was sputum EPO level (AUC
0.80). AUCs for other markers were Ex-eos 0.67, S-EPO 0.67, B-eos 0.66, ex-ECP 0.61,
and S-ECP 0.58. None of the differences were statistically significant, however.
In study IV, the upper reference limit in healthy subjects for blood eosinophils was
0.35 x 109/l, for the percentage of eosinophils in sputum 0.31. On the basis of these val-
ues the sensitivity of determination of blood eosinophils for diagnosis of asthma was
42% and the specificity was 93%. The corresponding figures relating to determination of
sputum eosinophils were 70% and 88% (Table 11). ROC curves relating to blood and
sputum eosinophil determinations were examined. AUCs relating to sputum eosinophil
determination (0.77) and blood eosinophil determinations (0.76) were similar.
47
In the healthy controls in study V, the upper reference limit for ECP in serum was
16.5 µg/l. For ECP in sputum it was 1987 µg/l, for EPO in sputum 3899 µg/l, for MPO in
sputum 1012 µg/L, and for HNL in sputum 14286 µg/L. Patients with respiratory symp-
toms more often had high serum ECP levels, high numbers of sputum eosinophils, and
high sputum ECP, MPO and HNL levels.
Table 11. Numbers and percentages of asthmatic children in study IV at baseline with results of
blood and sputum eosinophil determinations above reference values (results of both
determinations were available for 43 patients).
Result of blood eosinophil determination
Positive Negative
Sputum eosinophils Positive 13 (30%) 16 (37%)
Negative 3 (7%) 11 (26%)
Correlation between results
Correlation between clinical data and inflammatory markers
In study II, in patients with COPD, percentages of sputum neutrophils correlated inverse-
ly with FEV1 (r = -0.48, p < 0.05). No correlation of this kind was found in COPD pa-
tients in study I. In study III, there was a correlation between symptom scores relating to
wheezing and numbers of blood eosinophils (r = 0.50, p = 0.002) and sputum eosinophils
(r = 0.54, p < 0.0001). In smokers in study V, numbers of pack-years correlated weakly
with serum ECP levels (r = 0.2, p = 0.05). In study IV, numbers of blood eosinophils
(r =-0.41, p = 0.002) and numbers of sputum eosinophils (r =-0.53, p = 0.0002) correlat-
ed with airway responsiveness. The correlation between PEF (mean of morning and
evening values at baseline, % of predicted) and numbers of blood eosinophils was on the
margin of significance (r = -0.29, p = 0.05). When only data relating to atopic asthmatics
were analysed the correlation was significant (r = -0.44, p = 0.02). Numbers of blood
eosinophils correlated with mean symptom score (r = 0.28, p = 0.04).
Correlation between results relating to inflammatory markers
Correlations between results relating to inflammatory markers in studies I and III are
shown in Table 12. In study IV, there was a significant correlation between numbers of
blood eosinophils and sputum eosinophil percentages (Fig. 5) in relation to atopic asth-
matics (r = 0.65, p = 0.0003) but not in relation to non-atopic asthmatics (r = 0.22, p =
0.39). Numbers of sputum eosinophils correlated with numbers of sputum metachromatic
cells (r = 0.55, p < 0.0001), and numbers of sputum lymphocytes (r = 0.37, p = 0.01). In
study V, semiquantitative scores relating to sputum eosinophils on smears correlated with
sputum ECP levels (r = 0.33, p = 0.008) and sputum EPO levels (r = 0.39, p = 0.02). Se-
rum ECP levels correlated with sputum ECP levels (r = 0.33, p = 0.0004).
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Fig. 5. Correlation between numbers of blood eosinophils and numbers of sputum eosinophils in
asthmatic children at baseline (study IV), r = 0.56, p < 0.0001.
TREATMENT EFFECT
Study III : Follow-up in patients with respiratory symptoms
Of the 36 patients with respiratory symptoms, 31 (86%) were re-examined at three
months and one year. Four of the five patients unavailable for re-examination had re-
ceived placebo.
At three months, cough and total symptom scores, and numbers of blood eosinophils
in the BDP-treated group had decreased significantly from baseline (Fig. 6). In the place-
bo-treated group only total symptom score had decreased significantly. Cough score de-
creased to a significantly greater extent in the BDP-treated group than in the placebo-
treated group (p < 0.05).
After one year, 17 of 31 patients with respiratory symptoms (55%) continued to ex-
hibit symptoms but have normal lung function. Four patients (13%), two in the BDP
group and two in the placebo group, had developed asthma. Another 10 (32%), six in the
BDP and four in the placebo group, were free from symptoms, i.e. they did not meet the
criteria relating to symptoms. In the BDP-treated group total symptom score had de-
creased from 9.9 to 5.7, in the placebo group from 11.8 to 7.0. Two of the patients (both
in the placebo group) who had developed asthma had received treatment with inhaled
steroid after the first three-month period and were omitted from the one-year analysis. At
one year, the mean percentage of eosinophils in sputum had decreased in the BDP-treated
group from 3.0 at baseline to 1.3, in the placebo group from 2.3 at baseline to 0.3 (Fig.
6). Of the 29 patients that were included in one-year analysis, 11 of those 28 with ade-
quate sputum sample (39%) had increased sputum eosinophils at the start of the study. At
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Fig. 6. Changes from baseline in total symptom score (A), in cough score (B), in numbers of
blood eosinophils (C), and in percentages of sputum eosinophils (D) after three months (left
panel) and one year (right panel) in patients with respiratory symptoms (Study III). Each bar rep-
resents the mean change from baseline. Solid bars indicate BDP treatment, shaded bars indicate
placebo treatment.
*p < 0.05 in relation to differences between treatment groups
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one year, in 50% of them eosinophils persisted. Of the 17 patients (61%) that had no spu-
tum eosinophils at the first examination, 33% showed sputum eosinophils at one year.
Study IV
Six months of treatment
After six months of treatment with budesonide, children had significantly fewer exacer-
bations than those treated with cromoglycate (p < 0.01, Table 13). FEV1 had improved in
both groups but only in the budesonide group was the predicted  change from baseline in
terms of percentage of predicted FEV1 (with adjustment for child’s height) significant.
Symptoms (p < 0.001) and use of rescue medication (p < 0.01) decreased significantly
from baseline in the budesonide-treated groups (Table 13).
At six months, adequate sputum samples were obtained from 41/60 children (68%).
Representative samples at both baseline and six months were obtained from 34 children
(23 in the two budesonide groups, 11 in the cromoglycate group). Numbers of sputum
eosinophils decreased significantly in the budesonide groups (p = 0.003), but not in the
cromoglycate group (Table 13). Numbers of blood eosinophils and of sputum cells other
than eosinophils did not change significantly in any group. The three children who had
had more than 10% of eosinophils in sputum at baseline in the cromoglycate group expe-
rienced three, four and four exacerbations over the six-month period, and therefore re-
ceived treatment with budesonide by inhalation for about two months. Of the five pa-
tients with high percentages (> 10) of eosinophils in sputum in the budesonide groups,
one experienced one exacerbation during the months of treatment, the others none.
Eighteen months of treatment
After 18 months of treatment, the number of exacerbations was highest in the cromogly-
cate group (Table 13), significantly different from the number in the group that had re-
ceived regular treatment with budesonide at low doses (p < 0.05). No subject in the latter
group had to withdraw from the study because of hospitalisation as a result of asthma.
Two children in the placebo group, in which budesonide was used only during exacerba-
tions, were hospitalised between six and 18 months of treatment, and three children in
the cromoglycate group.
FEV1 had improved in all groups but only in the group that had received regular
treatment with budesonide was the change from baseline in terms of percentage of pre-
dicted FEV1 significant (p = 0.02, Table 13). Symptoms and use of rescue medication had
decreased in all groups in comparison with baseline but not in comparison with findings
at six months. Hyperresponsiveness to histamine did not decrease in any group in com-
parison with baseline.
At 18 months, adequate sputum samples were obtained from 36/60 children (60%).
Representative samples at both baseline and 18 months were obtained from 32 children
(10 in the group treated regularly with budesonide, 12 in the group that received budeso-
nide during exacerbations, and 10 in the cromoglycate group). Numbers of blood eosi-
nophils and differential counts of sputum cells were not significantly different from those
at baseline or six months (Table 13).
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Table 13. Study IV: Effects of treatment
Budesonide Budesonide-placebo Cromoglycate
(n = 19) (n = 20) (n = 21)
FVC,
 
l
Baseline 1.90 (1.03 - 2.96) 1.79 (1.18 - 2.40) 1.99 (1.30 - 3.11)
Change after six months 0.16 (-0.02 - 0.40)* 0.11 (-0.22 - 0.30)† 0.12 (-0.21 - 0.44)†
Change after 18 months 0.37 (0.15-0.58)* 0.34 (0.01-0.71)* 0.36 (0.09 - 0.71)*
FVC, % of predicted
Baseline 99.2 (88 -119) 101.2 (81 - 123) 101.7 (87 - 127)
Change after six months 0.86 (-23 - 16) 1.50 (-21 - 17) -0.31 (-15 - 14)
Change after 18 months 1.20 (-12 - 14) 0.79 (-15 - 16) -1.12 (-13 - 8.8)
FEV1, l
Baseline 1.60 (0.97 - 2.35) 1.49 (1.027 - 2.00) 1.69 (1.02 - 2.30)
Change after six months 0.15 (-0.70 - 0.50)† 0.09 (-0.70 - 0.40)‡ 0.05 (-0.91 - 0.30)†
Change after 18 months 0.33 (-0.53 - 0.80)† 0.29 (0.01 - 0.50)* 0.26 (-0.80 - 0.60)†
FEV1, % of predicted
Baseline 88.6 (71 - 102) 92.8 (75 - 111) 91.9 (74 - 113)
Change after six months 5.14 (-18 - 28)‡ 2.2 (-31 - 18) -0.38 (-11 - 12)
Change after 18 months 5.08 (-8.4 - 22)‡ -0.17 (-13 - 14) -0.57 (-8.2 - 6.3)
PEF,
 
l/min
Baseline 177 (123 - 231) 174 (98 - 230) 204 (114 - 280)
Change after six months 14.2 (-17 - 62)‡ -3.6 (-89 - 59) -3.4 (-76 - 57)
Change after 18 months 32.4 (2.4 - 55)† 28.3 (-40 - 95)‡ 24.3 (-20 - 106)‡
Symptoms (average score/day)
Baseline 4.2 (0.5 - 12) 4.4 (0.5 - 10) 4.4 (0.9 - 12)
Change after six months -2.2 (-6.4 - 2.7)† -2.1 (-9.3 - 3.6)‡ -1.7 (-8.0 - 5.6)
Change after 18 months -2.8 (-11.9 - 1.8)† -1.5 (-8.4 - 4.0)‡ -1.8 (-9.4 - 2.9)‡
Rescue medication (puffs/day)
Baseline 1.3 (0 - 4.9) 1.3 (0 - 3.1) 1.7 (0 - 6.3)
Change after six months -0.5 (-3.6 - 2.0) -0.8 (-3.1 - 0.7)† -0.5 (-4.4 - 3.7)
Change after 18 months -0.9 (-4.4 - 2.0)‡ -0.5 (-2.0 - 1.4)‡ -0.7 (-2.7 - 1.6)‡
Blood eosinophils, 109
Baseline 0.43 (0.13 - 1.38) 0.71 (0.02 - 3.54) 0.39 (0.03 - 1.79)
Change after six months 0.02 (-0.40 - 0.55) -0.31 (-1.94 - 0.40) -0.07 (-0.80 - 0.43)
Change after 18 months -0.002 (-0.73 - 0.69) -0.19 (-2.30 - 0.22) -0.06 (-0.69 - 0.83)
Sputum eosinophils, %
Baseline 5.9 (0 - 39) 6.9 (0 - 31) 4.5 (0 - 30)
Change after six months -2.0 (-14.7 - 0.9)‡ -5.9 (-29.9 - 0.3)† -3.6 (-22.0 - 2.2)
Change after 18 months -2.9 (-15.5 - 3.9) -3.8 (-29.9 - 3.5) -3.4 (-21.0 - 2.0)
Number of exacerbations
After six months** 0.5 (0 - 2) 0.7 (0 - 2) 1.4 (0 - 4)
After 18 months 1.6 (0 - 4) 2.8 (0 - 10) 3.1 (0 - 7)
Data are expressed as mean and range. *p<0.001, †p<0.01, ‡p<0.05, differences Vs baseline (Wilcoxon´s
signed rank test).**p<0.05 between treatment groups (Kruscall-Wallis test).
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DISCUSSION
STUDY POPULATIONS AND METHODS
Clinical characteristics of subjects
We used internationally accepted criteria to select COPD and asthma patients (ATS 1995,
NHBI 1997, Warner et al. 1998). These criteria are based on findings relating to symp-
toms and results of lung-function measurements. In the case of patients with chronic res-
piratory symptoms suggestive of asthma, the criteria for inclusion were symptoms that
made the clinician suspect asthma even though lung function did not meet the criteria al-
lowing a diagnosis of asthma. It could be argued that the patients classed as suffering
from respiratory symptoms were in fact suffering from mild asthma. Diagnosis of mild
asthma can be difficult, since results of measurements of lung function can remain nor-
mal for long periods, or may be conflicting (Siersted et al. 1996). To exclude asthmatics
from the group of patients classed as suffering from respiratory symptoms, low PEF and
FEV1 variability criteria (12%) and absence of increased bronchial responsiveness were
used. In patients diagnosed as suffering from respiratory symptoms, FEV1 increased on
average by only 2.5% 15 minutes after inhaling salbutamol in the bronchodilatation test.
Mean variability between morning and evening was 5.2% during PEF monitoring, and no
increased responsiveness to inhaled histamine was detected.
In study V, on the basis of results of clinical examinations and lung-function tests, 13
of 82 patients with persistent cough (16%) were diagnosed for the first time as suffering
from asthma. However, since no PEF follow-up or spirometry was undertaken in 15 sub-
jects, the possibility cannot be excluded that some of these subjects would have met the
criteria for asthma. The incidence of asthma may therefore have been slightly underesti-
mated. Taking into account the prevalence of asthma in the study population that under-
went lung-function testing, two or three subjects with asthma might have been missed.
Lung function was however tested in all patients with eosinophilic airway inflammation.
Since the study was carried out in patients attending for primary care, airway responsive-
ness could not be measured, nor could gastroscopy with 24-hour pH measurement be un-
dertaken (McGarvey et al. 1999).
All of the COPD patients were previous or current smokers. Mean pack-years were 52
and 37 in studies I and II, respectively. Most COPD patients were male. Smoking has been
found to be commoner in men than in women in both Belgium and Finland. COPD patients
were also significantly older than the patients in the other groups. In study II, the healthy
controls were matched for sex but not for age. We found no correlation between age and re-
sults of any measurements made. In the other studies, age- and sex-matching of patients and
controls were better. In study IV, the control children were slightly older than the asthmatic
children. This is one reason why the success rate in relation to induction of sputum produc-
tion was better in the healthy controls than in the asthmatic children.
No differences were found between smokers and non-smokers in any other disease
groups or in the healthy controls. Numbers of pack-years in relation to these subjects
were significantly lower than numbers for the COPD patients, and none of the smokers in
studies III and V were diagnosed (on the basis of results relating to lung function and du-
ration of symptoms) as suffering from chronic bronchitis or COPD (ATS 1995).
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Sputum induction
Safety
One of the aims of the studies reported here was to assess the safety of sputum induction,
especially in patients with COPD. In study I, the mean fall in FEV1 during induction from
baseline before bronchodilator administration was 8.5%, that from baseline after bron-
chodilator administration 10.7%. In study II, there were no falls in lung function during
sputum induction. In both studies all patients tolerated the procedure for induction of
sputum production well. No major side effects were reported but airway obstruction oc-
curred as a result of the induction procedure. Similar high-output nebulizers and similar
concentrations of hypertonic saline were used in the two studies. In study II, subjects
were pre-treated with 400 µg of inhaled salbutamol. In study I, 200 µg of inhaled salb-
utamol were used. Baseline lung function in the COPD patients was similar in both stud-
ies. However, in study II all patients except one were treated with inhaled steroids. Only
four of the patients (14%) in study I were treated in this way. All patients in the second
study were former smokers. Only two patients in study I had stopped smoking. These dif-
ferences could partly explain the different responses in the two studies. It is not clear
whether extent of bronchial obstruction depends on the amount of expectorate, the degree
of hypertonicity of the inhaled saline, the total amount inhaled or the rate of delivery, or
if bronchconstriction could be prevented by pre-treatment with higher doses of inhaled
salbutamol (Popov et al. 1995, Bacchi et al. 1997, Pavord 1998).
Pre-treatment with a bronchodilator did not prevent declines in FEV1, especially in
COPD patients with little or no FEV1 reversibility. Falls in FEV1 during sputum induction
correlated inversely with degree of reversibility in FEV1. This indicates that COPD pa-
tients with appreciable FEV1 reversibility may gain most from bronchodilator treatment
to prevent bronchoconstriction. Airway hyperreactivity and reversibility of airway ob-
struction are thought to be characteristic of asthma but can also be present in COPD. In-
creased airway responsiveness in smokers is a risk factor for accelerated decline in FEV1
with time, and hence for development of COPD (Ricjken et al. 1995). Disease severity as
assessed by symptom scores or results of lung-function measurements was not associated
with severity of bronchoconstriction. No correlations were found between degrees of
neutrophilic or eosinophilic airway inflammation and falls in FEV1 during induction.
Our results relating to safety of sputum induction in COPD patients are similar to re-
sults reported by others. Keatings et al. (1996) found a small but statistically significant
fall in FEV1 during induction in 17 COPD patients. Maestrelli et al. (1996) studied 33 pa-
tients with at least 10 pack-years of smoking history, 14 of whom exhibited airway ob-
struction. Falls in FEV1 of more than 20% were detected in only two subjects following
inhalation of hypertonic saline. In a study by Bhowmik et al. (2000) in 27 COPD patients
a mean fall of 11.7% in FEV1 was found during induction. Only one patient experienced a
fall in FEV1 of more than 20%.
In study III, sputum production was induced without pre-treatment in patients with
asthma or chronic respiratory symptoms suggestive of asthma. In these patients there
were also small falls in lung function during sputum induction. The greatest fall in PEF
was 17%. De la Fuente et al. (1998) found sputum induction to be safe even in patients
with uncontrolled asthma, with falls in FEV1 that never exceeded 20%. However, the pro-
cedure had to be stopped in 23% of cases because of the patients reporting side effects.
Changes in FEV1 were significantly more marked in patients with severe asthma than in
those less affected but there was no association between extent of control of the disease
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and poor tolerance of the procedure. In a study by Wong et al. (1997) 78 asthmatics with
baseline FEV1 after bronchodilator administration of more than 60% of predicted FEV1
were studied. Fourteen per cent exhibited bronchocontriction of more than 20%, another
8% falls of 10 to 20%. The greatest fall in FEV1 in their study was 69%. Changes in
FEV1 during sputum induction correlated significantly with baseline lung function and
percentages of eosinophils in induced sputum. In a study by Hunter et al. (1999), a low-
output ultrasonic nebulizer was used by 79 patients. A fall of 20% was seen in only three
subjects. In a later study by ten Brinke et al. (2001) it was shown that additional use of
short-acting β2-agonist as rescue medication during the days preceding sputum induction
increase the risk for bronchoconstriction.
In all of these previous studies on the safety of sputum induction in adult asthmatics
pre-treatment with a bronchodilator was used. We did not treat before induction because
we were studying patients with mild or moderate asthma (FEV1 more than 57% in all pa-
tients, mean 79%). The fact that significant falls in lung function occurred during induc-
tion of sputum even in mild disease highlights the importance of pre-treatment and moni-
toring of lung function during induction.
Sputum induction was found to be safe when asthmatic children were pre-treated
with a β2-agonist. This had previously been demonstrated in adolescents with severe sta-
ble asthma (Grootendors et al. 1999), even in acute childhood asthma (Gibson et al.
1999, Cai et al. 1998). Like Grootendors et al., we found a weak correlation between
baseline PEF values and PEF change during sputum induction. Sputum induction has
been shown to be safe in children with cystic fibrosis (De Boeck et al. 2000). When in-
ducing sputum in children, those concerned should have experience of evaluation of lung
function, and of identification and management of adverse effects.
Success of sputum induction
The overall baseline success rate of 82% is similar to rates reported by others (Pizzichini
et al. 1996a, int´Veen et al. 1996, Belda et al. 2000, Spavenello et al. 2000). It was lower
after anti-inflammatory treatment. In primary care, the rate of success in obtaining ade-
quate sputum samples was high (91%).
Sputum production has previously been induced mainly in children of six or more
years of age. We included 15 five-year-old children. Ten of them (67%) produced ade-
quate sputum samples. Success rate improved with age. It was 77% for the entire group
at baseline, 68% after six months of treatment and 60% after 18 months of treatment.
These rates are slightly better than rates reported by others in children on asthma medica-
tion (Wilson et al. 2000).
Sputum processing
Various sputum-processing methods were used in the studies described in this thesis. The
main difference related to selection of sputum masses from saliva as opposed to use of
entire expectorates. Selection of sputum results in squamous cell contamination being
less than that found when whole expectorate is used. In consequence, cell counting is
easier and quicker. Slides prepared from selected masses of sputum are, for example, bet-
ter suited to immunocytochemical analysis than slides prepared from entire expectorate.
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Concentrations of substances in the fluid phase are unaffected by the presence of saliva,
and accurate correction for dilution is possible. A disadvantage is that selection takes
time. Use of entire expectorate is quicker. We used selection in every study except study
IV. The latter was a longitudinal study to assess the effects of various anti-inflammatory
treatment strategies in children with asthma over 18-month periods. We felt it would be
difficult to select sputum after effective treatment over such a lengthy period. Contamina-
tion of sputum with squamous epithelial cells was relatively high. The reproducibility of
sputum cell counts was high in all patient groups using the selection method.
Recently, reference values for sputum differential cell counts in sputum selected
from saliva have been published (Belda et al. 2000, Spavenello et al. 2000). Induced spu-
tum samples from more than 200 control subjects in the studies mentioned were rich in
macrophages and neutrophils, poor in eosinophils, lymphocytes, metachromatic cells and
bronchial epithelial cells. Percentages of various types of cells were similar to those
found in our control groups.
INFLAMMATORY MARKERS
COPD
Differential cell counts relating to COPD patients revealed very high numbers of neu-
trophils and high concentrations of MPO compared to those relating to other patient
groups and healthy controls. Our findings are in line with previous findings of high per-
centages of intraluminal neutrophils (Thompson et al. 1989). It has been shown in studies
conducted using BAL that this neutrophilia increases significantly with severity of air-
way obstruction (Martin et al. 1985, Linden at al. 1993). This observation is in agreement
with our finding of an inverse correlation between percentages of neutrophils in induced
sputum and findings relating to FEV1 (study II). Similar results have been published by
others (Keatings et al. 1996, Balzano et al. 1999). However, findings in the other COPD
study reported here (study I) were different. It has also been shown that increased levels
of neutrophils in sputum correlate with rapid declines in lung function over 15-year fol-
low-up periods (Stânescu et al. 1996). Neutrophils probably pass into the airway lumen
because chemotactic factors are released by other airway cells, such as macrophages, T
lymphocytes and epithelial cells (Richman-Eisenstat et al. 1993, Keatings et al. 1996). It
has been shown that there is increased expression of adhesion molecules, such as E-se-
lectin on vessels and ICAM-1 on basal epithelial cells, in the bronchial mucosa of pa-
tients with chronic bronchitis with airway obstruction. This suggests such molecules are
involved in origination of the disease (DiStefaro et al. 1994).
When cytocentrifuge preparations were stained with a macrophage marker (CD68),
the percentage of positive cells was lower in COPD patients (17.9 ± 4.8) than in healthy
controls (71.2 ± 4.5). In both groups most macrophages were activated, as evidenced by
the high percentages of macrophages expressing the antigen M130, as recognised by the
antibody Ber-Mac 3 (Law et al. 1993)
Numbers of eosinophils in sputum were high in stable COPD patients. We and others
have previously published similar results (Balzano et al. 1999, Pizzichini et al. 1998a,
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Brightling et al. 2000a, Metso et al. 2001). Lacoste et al. (1993) have demonstrated high-
er numbers of eosinophils in blood, BAL fluid and bronchial biopsy specimens from
COPD patients than in normal subjects. However, the eosinophils were not degranulated
as they are in asthma. The mechanisms by which eosinophils pass into airways in asthma
and COPD may differ, since IL-5 expression has been found only in asthma patients (Sa-
etta et al. 1996).
The role played by eosinophils and value of anti-inflammatory medication in COPD
remain unclear, despite large multicentre trials relating to use of inhaled steroids (Pau-
wels et al. 1999, Burge et al. 2000). Results of some studies suggest that COPD patients
with airway eosinophilia may respond better to corticosteroid treatment than COPD pa-
tients without airway eosinophilia (Chanez et al. 1997, Pizzichini et al. 1998a, Brightling
et al. 2000a). In another study on inhaled and oral glucocorticoids in COPD no clinical
effects were seen, and none of the levels of inflammatory markers that were measured al-
tered (Keating et al. 1997c). Some of the stable chronic bronchitis patients evaluated in
their study also exhibited sputum eosinophilia. Eosinophils accounted in some cases for
as many as 10% of all inflammatory cells present. In a later study by the same group
(Culpitt et al. 1999), no changes in clinical parameters, numbers of sputum cells, and lev-
els of IL-8, proteases or antiproteases were found after one month of steroid treatment at
high dose by inhalation. All of the 13 subjects exhibited low numbers of sputum eosi-
nophils.
Saetta et al. (1994) have demonstrated marked airway eosinophilia during exacerba-
tions of chronic bronchitis. Patients with frequent exacerbations have higher baseline IL-
6 and IL-8 cytokine levels than other patients (Saetta et al. 1996). Determination of cy-
tokine levels may allow prediction of frequency of future exacerbations (Bhowmik et al.
2000).The effect of glucocorticoids has been shown to be better in relation to treatment
of exacerbations of COPD (Niewoehner et al. 1999). Further studies are needed to estab-
lish if there are sub-populations of COPD patients in whom eosinophils play a role in
origination of the disease, and in whom exacerbations might be worse than in other pa-
tients. The role of airway eosinophilia in disease progression is also unclear (Lebowitz et
al. 1995).
The low numbers of lymphocytes on Wright-Giemsa-stained slides is reflected in the
results of immunocytochemical analyses: only 2.1% and 1.8% of CD3-positive lym-
phocytes were seen in healthy controls and COPD patients, respectively. These low per-
centages of lymphocytes make it difficult to draw conclusions about the role played by
lymphocytes in origination of the disease. In addition, very few CD4- and CD8- and no
CD20- or CD25-positive cells were detected. It has been shown that dithiothreitol does
not reduce the reactivity of target molecules for immunocytochemistry after 10 minutes
of treatment (Girbis-Gabardo et al. 1994) but treatment for more than 20 minutes reduces
numbers of EG-2 positive cells (Popov et al. 1994). Since we exposed the cells to dithio-
threitol for no more than five minutes, the low numbers of positively staining cells are
not likely to have been a result of mucolytic treatment. Flow-cytometric analysis of spu-
tum lymphocytes is probably the best approach in relation to induced sputum.
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Asthma
High numbers of eosinophils and markers of eosinophil activation (EPO and ECP) were
found in blood and sputum from patients with asthma, both adult and children. All of the
asthma patients we studied had been newly diagnosed as suffering from the disease,
which had therefore not been previously treated with anti-inflammatory medication. We
found good correlation between numbers of blood and sputum eosinophils in both adults
and children with asthma. Peripheral blood eosinophilia discriminated at baseline be-
tween patients with asthma and healthy controls almost as well as discovery of high num-
bers of sputum eosinophils. Results of previous studies in adult asthmatics suggest that
the presence of high numbers of eosinophils in induced sputum samples discriminates
patients with asthma from control subjects better than results of determination of periph-
eral blood eosinophils (Pizzichini et al. 1997b). We found determination of numbers of
eosinophils in sputum to be better than determination of numbers of eosinophils in blood
for detecting asthma in children but the difference is not statistically significant. At base-
line, 30% of asthmatic children exhibited normal numbers of eosinophils in blood but
had unusually high numbers of eosinophils in sputum. Only 5% of asthmatic children ex-
hibited normal numbers of eosinophils in sputum and high levels of eosinophils in blood.
Atopic patients with asthma had significantly higher numbers of eosinophils in blood
than non-atopic asthmatics. Numbers of eosinophils in sputum did not differ significantly
between adult asthmatics with and without atopy. However, atopic children with asthma
had significantly larger numbers of eosinophils in sputum than non-atopic children with
asthma. It has been shown in adults that atopic subjects without asthma and patients with
seasonal allergic rhinitis can exhibit airway eosinophilia even without natural exposure to
the allergens concerned (Djukanovic et al. 1992b, Foresi et al. 1997, Vignola and Chanez
2001). Avoidance of allergens by children with asthma can significantly reduce the eosi-
nophilic phase of airway inflammation, and bronchial hyperresponsiveness (Piancentini
et al. 1996). The atopic children in our study IV were not exposed to any animals or to-
bacco smoke at home. Only three (8%) were allergic to house-dust mites. Sixteen (43%)
suffered from allergic rhinitis. However, it has been shown that children can be exposed
to significant amounts of cat and dog allergens in the environment (Lönnqvist et al. 1999,
Partti-Pellinen et al. 2000). Most baseline blood and sputum samples were collected out-
side the pollen season, but 12 samples (15%) were collected during summer months. The
latter were found not to differ significantly from samples collected during winter. We
found no significant differences between atopic and non-atopic healthy controls.
The role played by neutrophils in the progress of asthmatic inflammation is contro-
versial. In some studies it has been reported that neutrophils are important in chronic se-
vere asthma in adults (Jatakanon et al. 1999c) and children (Marquet et al. 1999). It has
even been suggested that there are at least two phenotypes of severe asthma, in which
eosinophils are either present or absent (Wenzel et al. 1999). Children with acute asthma
exhibit intense airway inflammation, in which neutrophils, eosinophils and mast cells are
involved (Twaddel et al. 1996, Gibson et al. 1999). In the studies reported here, which re-
late to mild or moderate asthma, numbers of sputum neutrophils were not higher than
normal. We found no correlation between numbers of sputum neutrophils and severity of
disease. In a study by Turner et al. (1995) asthma patients who had suffered clinical exac-
erbation exhibited no greater than 4% airway eosinophilia but signs of neutrophilic in-
flammation were evident. Similar results were found by Fahy et al. (1995b). Sputum
HNL and MPO values were not higher than normal in asthmatic patients.
Numbers of metachromatic cells in sputum were higher than normal in patients with
59
asthma and in patients with COPD, and correlated with numbers of eosinophils. Tryptase
is a serine endoprotease selectively released from mast cells. It has been shown that asth-
matics with increased levels of tryptase in sputum had higher sputum eosinophil counts
than normal (Bettiol et al. 1999).
Eosinophilic bronchial inflammation without asthma or COPD
We have suggested use of the term ”asthma-like inflammation” to describe the condition
suffered by patients with chronic respiratory symptoms suggestive of asthma, but normal
lung function, and signs of eosinophilic bronchial inflammation. The term would cover
the same kind of characteristics of inflammation (e.g. presence of eosinophils) as those
found in asthma but with a lesser degree of eosinophilic inflammation than in patients di-
agnosed as suffering from asthma.
Gibson et al. (1989b and 1995) described a condition in which chronic cough was as-
sociated with eosinophilic bronchitis. The condition presents as chronic productive cough
without no other asthma symptoms and normal spirometric findings. Airway responsive-
ness to methacholine was normal but sputum eosinophil counts were abnormally high.
They could be restored to normal by treatment with corticosteroid. The study population
was chosen on the basis of percentage of eosinophils in sputum (minimum 10). The con-
dition was fairly rare. Of 180 new referrals to the clinic concerned only seven met the cri-
teria established. The main difference between our patients and patients with eosinophilic
bronchitis would seem to be the existence of other symptoms suggestive of asthma. Pa-
tients with eosinophilic bronchitis produce sputum but experience no wheezing, dysp-
noea, or chest tightness. Cough was the main symptom in our patients but all also exhi-
bited some other respiratory symptom. The differences may seem minor but serve to em-
phasise the need for thorough clinical characterisation of patients in descriptive studies.
Recently, it has been suggested that the limit for diagnosis of eosinophilic bronchitis
should be 3% of eosinophils in sputum (Carney et al. 1997, Brightling et al. 1999a). Only
seven of 34 patients with respiratory symptoms suggestive of asthma in the study report-
ed here met this criterion indicating marked eosinophilia. In our experience percentages
of eosinophils in the sputum of healthy, truly asymptomatic individuals are very low
(mean 0.07). Thirty-eight per cent of patients with respiratory symptoms and 67% of pa-
tients with asthma in the study reported here exhibited eosinophilia, when this was de-
fined as a percentage (0.7) of eosinophils in sputum more than three standard deviations
above the normal mean. Recently published reference values for percentages of eosi-
nophils in sputum have been around 1% (Belda et al. 2000, Spanevello et al 2000).
In a recent study, the prevalence of eosinophilic bronchitis in 91 patients with isolat-
ed chronic cough was 12% (Brightling et al. 1999a). Brightling et al. modified a previ-
ously validated protocol for the study of chronic cough (Irwin et al. 1990). In study V,
eosinophils were found in sputum in 19% of patients with chronic cough in primary care.
Concentrations of the markers of eosinophil activation, ECP and EPO, were more often
abnormally high in serum and sputum in patients with chronic cough than in healthy in-
dividuals. Thirty-six per cent of those who had eosinophils in sputum were diagnosed as
suffering from asthma, 64% were not.
Several groups have studied patients with chronic respiratory symptoms (mainly
cough) and airway eosinophilia. A Japanese group has used the term atopic cough and
eosinophilic tracheobronchitis to describe the conditions suffered by patients with corti-
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costeroid-responsive non-productive cough, eosinophilia in induced sputum and bronchi-
al biopsy samples, normal spirometric values, normal airway responsiveness and in-
creased cough response to inhaled capsaicin (Fujimura et al. 2000). The term eosi-
nophilic bronchitis has also been used in relation to subjects with asthma-like symptoms
related to work and eosinophils in sputum but no asthma proper (Lemière et al. 1997).
Higher than normal numbers of mast cells and eosinophils have been found in BAL fluid
from patients with chronic non-productive cough caused by gastro-oesophageal reflux
(McGarvey et al. 1999). A Swedish group has used the term ”sensory hyperreactivity” in
relation to patients with cough, asthma-like symptoms and a positive response to the cap-
saicin provocation test (Millqvist et al. 1998). The subjects had normal lung function.
The nature of any airway inflammation present in such patients has yet to be studied.
All of our asthma patients exhibited increased bronchial responsiveness to inhaled
histamine except for those with respiratory symptoms suggestive of asthma. This finding
is in accordance with the results of inflammatory cells in sputum and suggests that rela-
tively severe inflammatory processes in asthmatic subjects could have led to airway re-
structuring (remodelling) and increased bronchial responsiveness that were mostly lack-
ing in the patients with just asthma-like inflammation. In ”classic” asthma, two factors
may affect functional outcome: a Th-2-mediated inflammation involving mast cells and
eosinophils, and airway-wall restructuring involving changes in airway epithelial, vascu-
lar, fibroblast, neural and smooth-muscle cell phenotypes. It has been shown that eosi-
nophilic bronchitis is associated with airway inflammation and increased release of va-
soactive and bronchoconstricting mediators (Brightling et al. 2000b). Levels of exhaled
NO have been shown to be higher than normal in eosinophilic bronchitis (Berlyne et al.
2000). Gibson et al. (1998a) have shown similar extents of BAL eosinophilia and cy-
tokine gene expression in patients with asthma and eosinophilic bronchitis. Niimi et al.
(1998) showed that numbers of eosinophils in bronchial biopsy samples from patients
with increased bronchial responsiveness were the same in both so-called ”cough variant
asthma” and in traditional asthma. It has been suggested that a possible reason for the
difference in airway responsiveness in patients with eosinophilic bronchitis and asthma is
that the epithelium remains intact in eosinophilic bronchitis (Brightling et al. 2000b). We
found no differences in numbers of epithelial cells in induced sputum samples in patients
with asthma and respiratory symptoms suggestive of asthma. Further studies of bronchial
biopsy material are required.
Airway eosinophilia can occur in otherwise healthy individuals during and after viral
infection (Trigg et al. 1996). We tried to exclude the effects of viral infection by includ-
ing only patients with no signs of respiratory infection during the preceding eight weeks.
Numbers of neutrophils, and levels of the markers of neutrophil activation HNL and
MPO, were no higher than normal in our patients with respiratory symptoms suggestive
of asthma. It has been shown that chronic dry cough can exist with higher than normal
numbers of neutrophils and levels of cytokines associated with neutrophil chemotaxis
(Jatakanon et al. 1999b).
Correlations between different inflammatory markers
In adults, numbers of blood eosinophils correlated best with serum EPO levels, in all
groups studied (no data available for COPD patients). Numbers of blood eosinophils cor-
related less well with serum ECP levels and numbers of eosinophils in sputum but the
correlations were statistically significant. In children with asthma, we found good corre-
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lation between numbers of eosinophils in blood and sputum. Numbers of eosinophils in
sputum correlated significantly with sputum EPO and ECP levels. When patients were
divided into groups according to diagnosis, a correlation was found only in relation to
asthmatics. Numbers of neutrophils in sputum correlated with sputum MPO and HNL
levels. They correlated with ECP levels better than numbers of eosinophils in sputum
overall, in all groups of patients except asthmatics. Levels of sputum ECP correlated
strongly with sputum MPO and HNL levels. These correlations suggests that factors
which prime neutrophils may also affect eosinophils. Venge et al. (1997) have reported
uptake of ECP by neutrophils. This could partly explain the correlation observed, since it
has been suggested that ECP occupies the same locations as MPO in secondary granules
of neutrophils (Sur et al. 1998).
Levels of sputum EPO and HNL have been measured in only a few previous studies.
Keatings et al. (1997b) found values similar to ours in asthma and COPD patients. A
slightly different sputum-handling method was used. It has been suggested that ECP and
EPO are released by different mechanisms, and that EPO might be the more sensitive in-
dicator of allergic inflammation (Karawajczyk et al. 1995, Metso et al. 2002).
The value of measuring inflammatory markers is questionable, given that counting
inflammatory cells yields similar results. Sputum processing to obtain cytospin slides and
differential cell counting are, however, laborious, and suitable only for research purposes.
Counting from smears gives only semiquantitative results. We have therefore been trying
to develop sputum processing and devise a simple method of measuring ECP and MPO
levels that could be applied in primary health-care settings (Metso et al. 2001).
EFFECTS  OF TREATMENT
In the patients with respiratory symptoms suggestive of asthma, three months of treat-
ment with inhaled BDP suppressed symptoms and resulted in declines in numbers of
eosinophils to greater extents than treatment with placebo. The difference between results
of treatment was significant in relation to the most important symptom, cough. In asthma,
eosinophilic inflammation has been found to be reversed or suppressed contemporane-
ously with improvement in lung function through treatment with inhaled steroid (Dju-
kanovic et al. 1992a, Jatakanon et al. 1999a). In eosinophilic bronchitis, treatment with
inhaled steroid has been shown to suppress symptoms and decrease numbers of eosi-
nophils in sputum (Gibson et al. 1995, Brightling et al. 2000c). However, the studies in
eosinophililic bronchitis were not placebo controlled.
The 60 asthmatic children who participated in study IV had been randomly selected
from 180 subjects participating in a study of early pharmacological intervention in child-
hood asthma (Turpeinen 2000). In the latter study, treatment with budesonide resulted in
50% fewer exacerbations than treatment with disodium cromoglycate treatment over an
18-month period. In our study, lung function, symptoms, use of rescue medication and
numbers of eosinophils in sputum did not alter statistically significantly in the cromogly-
cate group during the first six months. In some patients in the cromoglycate group there
were marked decreases in numbers of eosinophils in sputum. However, there had been
supportive treatment with inhaled budesonide by inhalation during exacerbations. Eight-
een of 21 children (86%) who started with cromoglycate needed at least one two-week
course of budesonide during the 18 months of the study.
Six months of treatment with inhaled budesonide decreased numbers of eosinophils
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in sputum with contemporaneous improvement clinical status but no significant changes
in numbers of eosinophils in blood. This finding suggests that determinations of numbers
of eosinophils in sputum may be a better means of following-up results of treatment than
determinations of numbers of eosinophils in blood.
After six months of treatment, children who had received budesonide were divided
into two groups of equal sizes. In one group the children continued with a low dose of
budesonide regularly, in the other the children received placebo and inhaled budesonide
only during exacerbations. No significant differences were seen between the two groups
at 18 months. This suggests that after clinical improvement has been seen during regular
treatment with inhaled steroid, periodic treatment might be sufficient to keep mild child-
hood asthma under control. However, all these patients should controlled regularly by
their physician.
CLINICAL IMPLICATIONS
There is general consensus as regards how moderate and severe asthma should be treated,
less agreement concerning treatment of mild asthma. Commencement of anti-inflamma-
tory therapy is not usually recommended until the patient has tried the effect of a short-
acting β2-agonist several times per week (NHLBI 1995). This situation has arisen largely
because not enough is known about the natural history of astma. It is also not clear
whether patients with just respiratory symptoms suggestive of asthma will develop asth-
ma proper. In the study reported here, four patients (13%) developed asthma during a
year of follow-up. The first three months of treatment received by these subjects differed.
In a Finnish study of children from seven to 12 years of age who had symptoms sugges-
tive of asthma but normal lung function, 33% developed clinical asthma during a two-
year follow-up period (Remes at al. 1998). Early detection of eosinophilic inflammation
would improve results of treatment with anti-inflammatory medication. This could affect
disease progress and the risk of developing chronic asthma. In general practice, bronchial
inflammation that may underlay symptoms is usually not characterised. Clinical judge-
ment is based on indirect information concerning bronchial status. In consequence, the
condition from which symptomatic patients with no apparent lung-function abnormality
are suffering is not diagnosed appropriately and courses of antibiotics, expectorants, anti-
tussives, antihistamines and β2-agonists, which will essentially have no effect on process-
es involving eosinophils, are prescribed.
The natural course of eosinophilic airway inflammation is not yet known. Many pa-
tients may never develop asthma but follow-up studies are needed (Brightling et al.
1999b). Three months of inhaled BDP in patients with respiratory symptoms did not pre-
vent the development of asthma in all patients in our study. On the other hand, eosi-
nophilic inflammation can heal spontaneously, especially if it has been caused by expo-
sure to an allergen, which ceases. Effective treatment of these patients may require pre-
scription of a course of inhaled steroids for two to three months. COPD patients in whose
eosinophils are found experience relatively rapid declines in lung function (Lebowitz et
al. 1995) and can benefit from anti-inflammatory therapy (Pizzichini et al. 1998a, Bright-
ling et al. 2000a).
Inflammatory changes such as infiltration of inflammatory cells into the mucosa, and
thickening of the basement membrane are visible in mucosal biopsy specimens taken
during endoscopic examination of the lungs in early stages of asthma, before dysfunction
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has become permanent (Laitinen et al. 1993). Mucosal inflammation obviously exists
well before development of pulmonary dysfunction. The interval between mucosal in-
flammation and initial symptoms and development of dysfunction is unknown. There are
indications that symptoms of mucosal inflammation need to exist for at least a year be-
fore increased bronchial susceptibility to constriction can be demonstrated by means of
challenge testing (Sovijärvi et al. 1993). We assessed asthmatics in whom duration of
symptoms had been fairly short (less than a year). It has been found in our clinic that
asthma can be diagnosed somewhat late in both adults and children (Haahtela et al.
1999). Even in the early stages of asthma in the studies reported here, there was marked
eosinophilic airway inflammation, which demonstrates the importance of early interven-
tion in asthma (Haahtela et al. 1991 and 1994).
We found no correlations between duration or severity of symptoms and levels of in-
flammatory markers in sputum. The only symptom that correlated with sputum eosi-
nophilia was wheezing, seen in both asthmatics and patients with respiratory symptoms
suggestive of asthma. Children with just recurrent cough are at lesser risk of developing
asthma than children with both cough and wheeze (Wright et al. 1996). In the study re-
ported here recurrent cough without wheeze was present in 38% of asthmatic children.
Although there were no significant differences in atopic status or baseline lung function
between the children who had both cough and wheezing and children who had just
cough, children in the latter group were less responsive to histamine and exhibited less
eosinophilic airway inflammation. However, children with just cough met the reversibili-
ty criterion for asthma, and did not respond differently to the anti-inflammatory asthma
medication used in this study from children with wheezing.
Determination of changes in numbers of eosinophils in sputum has been shown to be
a potentially useful means of predicting loss of control of asthma, as reflected by loss of
airway function (Jatakanon et al. 2000). However, some exacerbations appear to occur
via an eosinophil-independent mechanism (in´t Veen et al. 1999). Assessment of the na-
ture of an exacerbation could improve decisions regarding treatment.
A wide variety of relationships between clinical and functional parameters and re-
sults of measurements on induced sputum samples from patients with asthma has been
described (Rosi and Scano 1999). The relationship between severity of asthma as defined
by symptoms and results of lung-function tests and numbers of eosinophils in sputum is
at best weak (Iredale et al. 1994, Ronchi et al. 1997). Symptoms, results of lung-function
tests and bronchial hyperresponsiveness cannot predict determinations relating to cells in
sputum or biochemical parameters. This demonstrates the specific role that sputum
analysis can play in the assessment and monitoring of asthma.
FUTURE DIRECTIONS
Attempts have been made to devise a simplified method of sputum induction for use in
epidemiological studies (Gibson et al. 1998c). The procedure needs to be simplified fur-
ther if it is to be applicable in clinical practice (Metso et al. 2001). It remains to be seen
whether sputum analysis could be used daily at general practitioner level. Results of spu-
tum analysis can lead to better characterisation of asthma and COPD phenotypes, and of
mechanisms underlying chronic cough. They can be used to assess or predict responses
to treatments. Future studies will show whether asthma management with the aim of nor-
malising numbers of eosinophils in sputum results in better outcomes than standard ap-
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proaches, in which the aim of treatment is suppression of symptoms. (Sont et al. 1999).
Analysis of induced sputum samples can help with choice of additional therapy for asth-
ma patients with persistent symptoms who are taking inhaled steroids (Pizzichini et al.
1999b). Sputum induction could be used in relation to other airway diseases, such as tu-
berculosis, other infections and lung cancer, to evaluate inflammatory mechanisms and
altered gene expression, for example (Fleming et al. 1999). Induced sputum samples can
also be used to obtain airway cells for in vitro culture, allowing study of their functional
and phenotypic characteristics (Hamzaoui et al. 2000).
65
SUMMARY
The aim in study I was to assess safety of sputum induction in patients with COPD of
different severities. The subjects were 28 smokers with a mean baseline FEV1 of 1.8 L
(53% of the predicted) and mean reversibility of 2.5%. After pre-medication with 200 µg
of salbutamol, sputum was induced using increasing concentrations of saline in an ultra-
sonic nebulizer. The procedure was well tolerated. No patient reported a major side ef-
fect. However, the mean change during induction
 
from FEV1 before bronchodilator ad-
ministration was -8.5% and from the FEV1 after bronchodilator administration -10.7%.
Three subjects (11%) exhibited falls of more than 20% from baseline FEV1. A further 10
(36%) experienced falls of 10 to 20%. Patients with the greatest reversibility of airway
obstruction benefited most from bronchodilator pre-treatment because a statistically sig-
nificant inverse relationship between reversibility in FEV1 and fall in FEV1 during induc-
tion was found.
In study II, sputum was induced in 21 COPD patients with a mean FEV1 of 1.6 L
(54% of the predicted) and 16 healthy controls. Success rates, safety of the method, re-
producibility of cell counts and differences in cell counts were investigated in both
groups. All subjects produced adequate sputum samples. Induction did not alter spiromet-
ric values.  Marked sputum neutrophilia was noted in patients with COPD. Both within-
investigator and between-investigator cell-count reproducibility were high for major cell
types. In patients with COPD, an inverse correlation was noted between percentages of
neutrophils and FEV1 values. Immunostaining revealed very few lymphocytes.
In study III, we tested the hypothesis that eosinophilic airway inflammation is
present in many patients who present with respiratory symptoms suggestive of asthma
but normal lung function. Thirty-six consecutive patients of this kind were studied.
Twenty-five asthmatics and 43 healthy volunteers served as controls. Signs of eosi-
nophilic inflammation were studied in blood and induced sputum samples. Patients with
respiratory symptoms were treated on a single-blind basis with inhaled beclomethasone
dipropionate (BDP) (800 µg daily) or with placebo for three months. They were
re-examined at three months and one year. Patients with respiratory symptoms had higher
numbers of blood and sputum eosinophils than healthy individuals but degrees of eosi-
nophilic inflammation were less than in asthmatics. Three months of treatment with BDP
significantly reduced total symptom scores, cough scores, and numbers of eosinophils in
blood. For cough, the improvement was significantly greater than that achieved with pla-
cebo. Of 31 patients followed-up for one year, 17 (55%) still exhibited symptoms but had
normal lung function. Four patients (13%) had developed asthma. Ten (32%) had become
symptom-free.
Study IV took the form of a double-blind randomised study in 60 children, five to 10
years of age, with newly diagnosed asthma Thirty-nine children received budesonide
(800 µg/day) for one month, 400 µg/day for five months, and budesonide (n = 19) (200
µg/day) or placebo (n = 20) for 12 months. Patients in a third group (n = 21) were treated
with disodium cromoglycate (30 mg/day) for 18 months. Asthma exacerbations in all
groups were treated with budesonide (800 µg/day) for two weeks. At baseline, a control
group of 17 healthy children was studied. Diaries were used to record respiratory symp-
toms and lung function throughout the study. Airway inflammation was assessed by ex-
amination of induced sputum samples. At baseline, the asthmatic children had more eosi-
nophils in blood and sputum than the controls, and more metachromatic cells in sputum.
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Eosinophilic inflammation was most pronounced in children with atopic asthma. After
six months of treatment, the children who had been treated with budesonide had had sig-
nificantly fewer exacerbations than those treated with cromoglycate. Treatment with
budesonide significantly improved lung function, decreased symptoms, use of rescue
medication and numbers of eosinophils in sputum. Regular treatment with inhaled bude-
sonide for 18 months resulted in further improvements in lung function and symptoms
but the changes were not significantly different from those in the other two groups.
In study V, using simplified methods of sputum induction and processing of sputum
samples, we determined whether eosinophilic airway inflammation was associated with
prolonged cough. Eighty-two patients who had had cough for more than one month were
enrolled into the study, from six primary-health-care centres. Patients with known pulmo-
nary disease, including asthma and COPD, whose cough was known to have another
cause, or who had recently suffered a respiratory infection were excluded. Fifty-three
healthy individuals served as controls. Sputum production was induced by inhalation of
3% saline. Inflammatory cells in smears were studied semi-quantitatively. Concentrations
of eosinophil cationic protein (ECP), eosinophil peroxidase (EPO), myeloperoxidase
(MPO) and human neutrophilic lipocalin (HNL) were determined. Sputum induction
proved safe and adequate samples were obtained from 91%. Sputum eosinophilia (eosi-
nophils accounting for more than 5% of all cells in smears) was present in 14 patients
with prolonged cough (19%) but in no healthy individual. Five of the 14 individuals
(36%) who exhibited sputum eosinophilia appeared to have asthma, while nine of the 14
(64%) did not. Concentrations of ECP and EPO were higher in patients with prolonged
cough than in healthy individuals.
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CONCLUSIONS
• Sputum induction by inhalation of hypertonic saline can result in bronchial
obstruction. Our results highlight the importance of pre-treatment with
bronchodilators and monitoring of lung function during sputum induction. If
appropriate methods are used sputum induction is a safe and reproducible method
allowing to study airway inflammation in various respiratory diseases.
• Marked sputum neurophilia is present in patiens with COPD. However, there is a
subgroup of COPD patiens with eosinophilic airway inflammation.
• Patients exist who have symptoms suggestive of asthma and signs of
eosinophilic bronchial inflammation but no significant airflow limitation. Such
patients respond to treatment with inhaled steroid. The condition from which they
suffer has no agreed definition or diagnostic criteria. Its occurrence and effects of
treatments on it have not been systematically studied.
• Sputum induction can be safely and successfully used in studying airway
inflammation in children with newly diagnosed asthma. Evidence of eosinophilic
inflammation can be seen in induced sputum samples, especially in atopic
asthmatics. Six months of treatment with inhaled budesonide controlled asthma
well, decreased numbers of eosinophils in sputum and improved lung function.
Regular treatment with low doses of inhaled steroid for 18 months resulted in
further clinical improvement but results were equally good with periodic treatment
during exacerbations only. The results may indicate a new strategy for treatment of
newly detected mild childhood asthma, in which regular therapy with inhaled
steroids may, if effective, be followed by treatment at intervals.
• Eosinophilic airway inflammation is a fairly common cause of chronic cough in
primary care, even in patients not suffering from asthma or COPD, or in whom no
other cause of cough is known to exist. Induced sputum samples obtained in health
centres can be studied in central laboratories. Detection of eosinophilic airway
inflammation could aid decisions regarding treatment.
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